Author: "Valantinas J." - Searchworks@Jio Institute Digital Library Search Results

Your search keyword '"Valantinas J."' showing total 101 results

Start Over Author "Valantinas J."

101 results on '"Valantinas J."'

1. A global research priority agenda to advance public health responses to fatty liver disease

Author: Lazarus, J, Mark, H, Allen, A, Arab, J, Carrieri, P, Noureddin, M, Alazawi, W, Alkhouri, N, Alqahtani, S, Arrese, M, Bataller, R, Berg, T, Brennan, P, Burra, P, Castro-Narro, G, Cortez-Pinto, H, Cusi, K, Dedes, N, Duseja, A, Francque, S, Hagstrom, H, Huang, T, Wajcman, D, Kautz, A, Kopka, C, Krag, A, Miller, V, Newsome, P, Rinella, M, Romero, D, Sarin, S, Silva, M, Spearman, C, Tsochatzis, E, Valenti, L, Villota-Rivas, M, Zelber-Sagi, S, Schattenberg, J, Wong, V, Younossi, Z, Aberg, F, Adams, L, Al-Naamani, K, Albadawy, R, Alexa, Z, Allison, M, Alnaser, F, Alswat, K, Alvares-da-Silva, M, Alvaro, D, Alves-Bezerra, M, Andrade, R, Anstee, Q, Awuku, Y, Baatarkhuu, O, Baffy, G, Bakieva, S, Bansal, M, Barouki, R, Batterham, R, Behling, C, Belfort-DeAguiar, R, Berzigotti, A, Betel, M, Bianco, C, Bosi, E, Boursier, J, Brunt, E, Bugianesi, E, Byrne, C, Cabrera Cabrejos, M, Caldwell, S, Carr, R, Castellanos Fernandez, M, Castera, L, Castillo-Lopez, M, Caussy, C, Cerda-Reyes, E, Ceriello, A, Chan, W, Chang, Y, Charatcharoenwitthaya, P, Chavez-Tapia, N, Chung, R, Colombo, M, Coppell, K, Cotrim, H, Craxi, A, Crespo, J, Dassanayake, A, Davidson, N, De Knegt, R, de Ledinghen, V, Demir, M, Desalegn, H, Diago, M, Dillon, J, Dimmig, B, Dirac, M, Dirchwolf, M, Dufour, J, Dvorak, K, Ekstedt, M, El-Kassas, M, Elsanousi, O, Elsharkawy, A, Elwakil, R, Eskridge, W, Eslam, M, Esmat, G, Fan, J, Ferraz, M, Flisiak, R, Fortin, D, Fouad, Y, Freidman, S, Fuchs, M, Gadano, A, Gastaldelli, A, Geerts, A, Geier, A, George, J, Gerber, L, Ghazinyan, H, Gheorghe, L, Kile, D, Girala, M, Boon Bee, G, Goossens, N, Graupera, I, Gronbaek, H, Hamid, S, Hebditch, V, Henry, Z, Hickman, I, Hobbs, L, Hocking, S, Hofmann, W, Idilman, R, Iruzubieta, P, Isaacs, S, Isakov, V, Ismail, M, Jamal, M, Jarvis, H, Jepsen, P, Jornayvaz, F, Sudhamshu, K, Kakizaki, S, Karpen, S, Kawaguchi, T, Keating, S, Khader, Y, Kim, S, Kim, W, Kleiner, D, Koek, G, Joseph Komas, N, Kondili, L, Koot, B, Korenjak, M, Kotsiliti, E, Koulla, Y, Kugelmas, C, Kugelmas, M, Labidi, A, Lange, N, Lavine, J, Lazo, M, Leite, N, Lin, H, Lkhagvaa, U, Long, M, Lopez-Jaramillo, P, Lozano, A, Macedo, M, Malekzadeh, R, Marchesini, G, Marciano, S, Martinez, K, Martinez Vazquez, S, Mateva, L, Mato, J, Nlombi, C, Mccary, A, Mcintyre, J, Mckee, M, Mendive, J, Mikolasevic, I, Miller, P, Milovanovic, T, Milton, T, Moreno-Alcantar, R, Morgan, T, Motala, A, Muris, J, Musso, C, Nava-Gonzalez, E, Negro, F, Nersesov, A, Neuschwander-Tetri, B, Nikolova, D, Norris, S, Novak, K, Ocama, P, Ong, J, Ong-Go, A, Onyekwere, C, Padilla, M, Pais, R, Pan, C, Panduro, A, Panigrahi, M, Papatheodoridis, G, Paruk, I, Patel, K, Goncalves, C, Figueroa, M, Perez-Escobar, J, Pericas, J, Perseghin, G, Pessoa, M, Petta, S, Marques Souza de Oliveira, C, Prabhakaran, D, Pyrsopoulous, N, Rabiee, A, Ramji, A, Ratziu, V, Ravendhran, N, Ray, K, Roden, M, Romeo, S, Romero-Gomez, M, Rotman, Y, Rouabhia, S, Rowe, I, Sadirova, S, Alkhatry, M, Salupere, R, Satapathy, S, Schwimmer, J, Sebastiani, G, Seim, L, Seki, Y, Serme, A, Shapiro, D, Sharvadze, L, Shaw, J, Shawa, I, Shenoy, T, Shibolet, O, Shimakawa, Y, Shubrook, J, Singh, S, Sinkala, E, Skladany, L, Skrypnyk, I, Song, M, Sookoian, S, Sridharan, K, Stefan, N, Stine, J, Stratakis, N, Sheriff, D, Sundaram, S, Svegliati-Baroni, G, Swain, M, Tacke, F, Taheri, S, Tan, S, Tapper, E, Targher, G, Tcaciuc, E, Thiele, M, Tiniakos, D, Tolmane, I, Torre, A, Torres, E, Treeprasertsuk, S, Trenell, M, Turcan, S, Turcanu, A, Valantinas, J, van Kleef, L, Velarde Ruiz Velasco, J, Vesterhus, M, Vilar-Gomez, E, Waked, I, Wattacheril, J, Wedemeyer, H, Wilkins, F, Willemse, J, Wong, R, Yilmaz, Y, Yki-Jarvinen, H, Yu, M, Yumuk, V, Zeybel, M, Zheng, K, Zheng, M, Lazarus J. V., Mark H. E., Allen A. M., Arab J. P., Carrieri P., Noureddin M., Alazawi W., Alkhouri N., Alqahtani S. A., Arrese M., Bataller R., Berg T., Brennan P. N., Burra P., Castro-Narro G. E., Cortez-Pinto H., Cusi K., Dedes N., Duseja A., Francque S. M., Hagstrom H., Huang T. T. -K., Wajcman D. I., Kautz A., Kopka C. J., Krag A., Miller V., Newsome P. N., Rinella M. E., Romero D., Sarin S. K., Silva M., Spearman C. W., Tsochatzis E. A., Valenti L., Villota-Rivas M., Zelber-Sagi S., Schattenberg J. M., Wong V. W. -S., Younossi Z. M., Aberg F., Adams L., Al-Naamani K., Albadawy R. M., Alexa Z., Allison M., Alnaser F. A., Alswat K., Alvares-da-Silva M. R., Alvaro D., Alves-Bezerra M., Andrade R. J., Anstee Q. M., Awuku Y. A., Baatarkhuu O., Baffy G., Bakieva S., Bansal M. B., Barouki R., Batterham R. L., Behling C., Belfort-DeAguiar R., Berzigotti A., Betel M., Bianco C., Bosi E., Boursier J., Brunt E. M., Bugianesi E., Byrne C. J., Cabrera Cabrejos M. C., Caldwell S., Carr R., Castellanos Fernandez M. I., Castera L., Castillo-Lopez M. G., Caussy C., Cerda-Reyes E., Ceriello A., Chan W. -K., Chang Y., Charatcharoenwitthaya P., Chavez-Tapia N., Chung R. T., Colombo M., Coppell K., Cotrim H. P., Craxi A., Crespo J., Dassanayake A., Davidson N. O., De Knegt R., de Ledinghen V., Demir M., Desalegn H., Diago M., Dillon J. F., Dimmig B., Dirac M. A., Dirchwolf M., Dufour J. -F., Dvorak K., Ekstedt M., El-Kassas M., Elsanousi O. M., Elsharkawy A. M., Elwakil R., Eskridge W., Eslam M., Esmat G., Fan J. -G., Ferraz M. L., Flisiak R., Fortin D., Fouad Y., Freidman S. L., Fuchs M., Gadano A., Gastaldelli A., Geerts A., Geier A., George J., Gerber L. H., Ghazinyan H., Gheorghe L., Kile D. G., Girala M., Boon Bee G. G., Goossens N., Graupera I., Gronbaek H., Hamid S., Hebditch V., Henry Z., Hickman I. J., Hobbs L. A., Hocking S. L., Hofmann W. P., Idilman R., Iruzubieta P., Isaacs S., Isakov V. A., Ismail M. H., Jamal M. H., Jarvis H., Jepsen P., Jornayvaz F., Sudhamshu K. C., Kakizaki S., Karpen S., Kawaguchi T., Keating S. E., Khader Y., Kim S. U., Kim W., Kleiner D. E., Koek G., Joseph Komas N. P., Kondili L. A., Koot B. G., Korenjak M., Kotsiliti E., Koulla Y., Kugelmas C., Kugelmas M., Labidi A., Lange N. F., Lavine J. E., Lazo M., Leite N., Lin H. -C., Lkhagvaa U., Long M. T., Lopez-Jaramillo P., Lozano A., Macedo M. P., Malekzadeh R., Marchesini G., Marciano S., Martinez K., Martinez Vazquez S. E., Mateva L., Mato J. M., Nlombi C. M., McCary A. G., McIntyre J., McKee M., Mendive J. M., Mikolasevic I., Miller P. S., Milovanovic T., Milton T., Moreno-Alcantar R., Morgan T. R., Motala A., Muris J., Musso C., Nava-Gonzalez E. J., Negro F., Nersesov A. V., Neuschwander-Tetri B. A., Nikolova D., Norris S., Novak K., Ocama P., Ong J. P., Ong-Go A., Onyekwere C., Padilla M., Pais R., Pan C., Panduro A., Panigrahi M. K., Papatheodoridis G., Paruk I., Patel K., Goncalves C. P., Figueroa M. P., Perez-Escobar J., Pericas J. M., Perseghin G., Pessoa M. G., Petta S., Marques Souza de Oliveira C. P., Prabhakaran D., Pyrsopoulous N., Rabiee A., Ramji A., Ratziu V., Ravendhran N., Ray K., Roden M., Romeo S., Romero-Gomez M., Rotman Y., Rouabhia S., Rowe I. A., Sadirova S., Alkhatry M. S., Salupere R., Satapathy S. K., Schwimmer J. B., Sebastiani G., Seim L., Seki Y., Serme A. K., Shapiro D., Sharvadze L., Shaw J. E., Shawa I. T., Shenoy T., Shibolet O., Shimakawa Y., Shubrook J. H., Singh S. P., Sinkala E., Skladany L., Skrypnyk I., Song M. J., Sookoian S., Sridharan K., Stefan N., Stine J. G., Stratakis N., Sheriff D. S., Sundaram S. S., Svegliati-Baroni G., Swain M. G., Tacke F., Taheri S., Tan S. -S., Tapper E. B., Targher G., Tcaciuc E., Thiele M., Tiniakos D., Tolmane I., Torre A., Torres E. A., Treeprasertsuk S., Trenell M., Turcan S., Turcanu A., Valantinas J., van Kleef L. A., Velarde Ruiz Velasco J. A., Vesterhus M., Vilar-Gomez E., Waked I., Wattacheril J., Wedemeyer H., Wilkins F., Willemse J., Wong R. J., Yilmaz Y., Yki-Jarvinen H., Yu M. -L., Yumuk V., Zeybel M., Zheng K. I., Zheng M. -H., Lazarus, J, Mark, H, Allen, A, Arab, J, Carrieri, P, Noureddin, M, Alazawi, W, Alkhouri, N, Alqahtani, S, Arrese, M, Bataller, R, Berg, T, Brennan, P, Burra, P, Castro-Narro, G, Cortez-Pinto, H, Cusi, K, Dedes, N, Duseja, A, Francque, S, Hagstrom, H, Huang, T, Wajcman, D, Kautz, A, Kopka, C, Krag, A, Miller, V, Newsome, P, Rinella, M, Romero, D, Sarin, S, Silva, M, Spearman, C, Tsochatzis, E, Valenti, L, Villota-Rivas, M, Zelber-Sagi, S, Schattenberg, J, Wong, V, Younossi, Z, Aberg, F, Adams, L, Al-Naamani, K, Albadawy, R, Alexa, Z, Allison, M, Alnaser, F, Alswat, K, Alvares-da-Silva, M, Alvaro, D, Alves-Bezerra, M, Andrade, R, Anstee, Q, Awuku, Y, Baatarkhuu, O, Baffy, G, Bakieva, S, Bansal, M, Barouki, R, Batterham, R, Behling, C, Belfort-DeAguiar, R, Berzigotti, A, Betel, M, Bianco, C, Bosi, E, Boursier, J, Brunt, E, Bugianesi, E, Byrne, C, Cabrera Cabrejos, M, Caldwell, S, Carr, R, Castellanos Fernandez, M, Castera, L, Castillo-Lopez, M, Caussy, C, Cerda-Reyes, E, Ceriello, A, Chan, W, Chang, Y, Charatcharoenwitthaya, P, Chavez-Tapia, N, Chung, R, Colombo, M, Coppell, K, Cotrim, H, Craxi, A, Crespo, J, Dassanayake, A, Davidson, N, De Knegt, R, de Ledinghen, V, Demir, M, Desalegn, H, Diago, M, Dillon, J, Dimmig, B, Dirac, M, Dirchwolf, M, Dufour, J, Dvorak, K, Ekstedt, M, El-Kassas, M, Elsanousi, O, Elsharkawy, A, Elwakil, R, Eskridge, W, Eslam, M, Esmat, G, Fan, J, Ferraz, M, Flisiak, R, Fortin, D, Fouad, Y, Freidman, S, Fuchs, M, Gadano, A, Gastaldelli, A, Geerts, A, Geier, A, George, J, Gerber, L, Ghazinyan, H, Gheorghe, L, Kile, D, Girala, M, Boon Bee, G, Goossens, N, Graupera, I, Gronbaek, H, Hamid, S, Hebditch, V, Henry, Z, Hickman, I, Hobbs, L, Hocking, S, Hofmann, W, Idilman, R, Iruzubieta, P, Isaacs, S, Isakov, V, Ismail, M, Jamal, M, Jarvis, H, Jepsen, P, Jornayvaz, F, Sudhamshu, K, Kakizaki, S, Karpen, S, Kawaguchi, T, Keating, S, Khader, Y, Kim, S, Kim, W, Kleiner, D, Koek, G, Joseph Komas, N, Kondili, L, Koot, B, Korenjak, M, Kotsiliti, E, Koulla, Y, Kugelmas, C, Kugelmas, M, Labidi, A, Lange, N, Lavine, J, Lazo, M, Leite, N, Lin, H, Lkhagvaa, U, Long, M, Lopez-Jaramillo, P, Lozano, A, Macedo, M, Malekzadeh, R, Marchesini, G, Marciano, S, Martinez, K, Martinez Vazquez, S, Mateva, L, Mato, J, Nlombi, C, Mccary, A, Mcintyre, J, Mckee, M, Mendive, J, Mikolasevic, I, Miller, P, Milovanovic, T, Milton, T, Moreno-Alcantar, R, Morgan, T, Motala, A, Muris, J, Musso, C, Nava-Gonzalez, E, Negro, F, Nersesov, A, Neuschwander-Tetri, B, Nikolova, D, Norris, S, Novak, K, Ocama, P, Ong, J, Ong-Go, A, Onyekwere, C, Padilla, M, Pais, R, Pan, C, Panduro, A, Panigrahi, M, Papatheodoridis, G, Paruk, I, Patel, K, Goncalves, C, Figueroa, M, Perez-Escobar, J, Pericas, J, Perseghin, G, Pessoa, M, Petta, S, Marques Souza de Oliveira, C, Prabhakaran, D, Pyrsopoulous, N, Rabiee, A, Ramji, A, Ratziu, V, Ravendhran, N, Ray, K, Roden, M, Romeo, S, Romero-Gomez, M, Rotman, Y, Rouabhia, S, Rowe, I, Sadirova, S, Alkhatry, M, Salupere, R, Satapathy, S, Schwimmer, J, Sebastiani, G, Seim, L, Seki, Y, Serme, A, Shapiro, D, Sharvadze, L, Shaw, J, Shawa, I, Shenoy, T, Shibolet, O, Shimakawa, Y, Shubrook, J, Singh, S, Sinkala, E, Skladany, L, Skrypnyk, I, Song, M, Sookoian, S, Sridharan, K, Stefan, N, Stine, J, Stratakis, N, Sheriff, D, Sundaram, S, Svegliati-Baroni, G, Swain, M, Tacke, F, Taheri, S, Tan, S, Tapper, E, Targher, G, Tcaciuc, E, Thiele, M, Tiniakos, D, Tolmane, I, Torre, A, Torres, E, Treeprasertsuk, S, Trenell, M, Turcan, S, Turcanu, A, Valantinas, J, van Kleef, L, Velarde Ruiz Velasco, J, Vesterhus, M, Vilar-Gomez, E, Waked, I, Wattacheril, J, Wedemeyer, H, Wilkins, F, Willemse, J, Wong, R, Yilmaz, Y, Yki-Jarvinen, H, Yu, M, Yumuk, V, Zeybel, M, Zheng, K, Zheng, M, Lazarus J. V., Mark H. E., Allen A. M., Arab J. P., Carrieri P., Noureddin M., Alazawi W., Alkhouri N., Alqahtani S. A., Arrese M., Bataller R., Berg T., Brennan P. N., Burra P., Castro-Narro G. E., Cortez-Pinto H., Cusi K., Dedes N., Duseja A., Francque S. M., Hagstrom H., Huang T. T. -K., Wajcman D. I., Kautz A., Kopka C. J., Krag A., Miller V., Newsome P. N., Rinella M. E., Romero D., Sarin S. K., Silva M., Spearman C. W., Tsochatzis E. A., Valenti L., Villota-Rivas M., Zelber-Sagi S., Schattenberg J. M., Wong V. W. -S., Younossi Z. M., Aberg F., Adams L., Al-Naamani K., Albadawy R. M., Alexa Z., Allison M., Alnaser F. A., Alswat K., Alvares-da-Silva M. R., Alvaro D., Alves-Bezerra M., Andrade R. J., Anstee Q. M., Awuku Y. A., Baatarkhuu O., Baffy G., Bakieva S., Bansal M. B., Barouki R., Batterham R. L., Behling C., Belfort-DeAguiar R., Berzigotti A., Betel M., Bianco C., Bosi E., Boursier J., Brunt E. M., Bugianesi E., Byrne C. J., Cabrera Cabrejos M. C., Caldwell S., Carr R., Castellanos Fernandez M. I., Castera L., Castillo-Lopez M. G., Caussy C., Cerda-Reyes E., Ceriello A., Chan W. -K., Chang Y., Charatcharoenwitthaya P., Chavez-Tapia N., Chung R. T., Colombo M., Coppell K., Cotrim H. P., Craxi A., Crespo J., Dassanayake A., Davidson N. O., De Knegt R., de Ledinghen V., Demir M., Desalegn H., Diago M., Dillon J. F., Dimmig B., Dirac M. A., Dirchwolf M., Dufour J. -F., Dvorak K., Ekstedt M., El-Kassas M., Elsanousi O. M., Elsharkawy A. M., Elwakil R., Eskridge W., Eslam M., Esmat G., Fan J. -G., Ferraz M. L., Flisiak R., Fortin D., Fouad Y., Freidman S. L., Fuchs M., Gadano A., Gastaldelli A., Geerts A., Geier A., George J., Gerber L. H., Ghazinyan H., Gheorghe L., Kile D. G., Girala M., Boon Bee G. G., Goossens N., Graupera I., Gronbaek H., Hamid S., Hebditch V., Henry Z., Hickman I. J., Hobbs L. A., Hocking S. L., Hofmann W. P., Idilman R., Iruzubieta P., Isaacs S., Isakov V. A., Ismail M. H., Jamal M. H., Jarvis H., Jepsen P., Jornayvaz F., Sudhamshu K. C., Kakizaki S., Karpen S., Kawaguchi T., Keating S. E., Khader Y., Kim S. U., Kim W., Kleiner D. E., Koek G., Joseph Komas N. P., Kondili L. A., Koot B. G., Korenjak M., Kotsiliti E., Koulla Y., Kugelmas C., Kugelmas M., Labidi A., Lange N. F., Lavine J. E., Lazo M., Leite N., Lin H. -C., Lkhagvaa U., Long M. T., Lopez-Jaramillo P., Lozano A., Macedo M. P., Malekzadeh R., Marchesini G., Marciano S., Martinez K., Martinez Vazquez S. E., Mateva L., Mato J. M., Nlombi C. M., McCary A. G., McIntyre J., McKee M., Mendive J. M., Mikolasevic I., Miller P. S., Milovanovic T., Milton T., Moreno-Alcantar R., Morgan T. R., Motala A., Muris J., Musso C., Nava-Gonzalez E. J., Negro F., Nersesov A. V., Neuschwander-Tetri B. A., Nikolova D., Norris S., Novak K., Ocama P., Ong J. P., Ong-Go A., Onyekwere C., Padilla M., Pais R., Pan C., Panduro A., Panigrahi M. K., Papatheodoridis G., Paruk I., Patel K., Goncalves C. P., Figueroa M. P., Perez-Escobar J., Pericas J. M., Perseghin G., Pessoa M. G., Petta S., Marques Souza de Oliveira C. P., Prabhakaran D., Pyrsopoulous N., Rabiee A., Ramji A., Ratziu V., Ravendhran N., Ray K., Roden M., Romeo S., Romero-Gomez M., Rotman Y., Rouabhia S., Rowe I. A., Sadirova S., Alkhatry M. S., Salupere R., Satapathy S. K., Schwimmer J. B., Sebastiani G., Seim L., Seki Y., Serme A. K., Shapiro D., Sharvadze L., Shaw J. E., Shawa I. T., Shenoy T., Shibolet O., Shimakawa Y., Shubrook J. H., Singh S. P., Sinkala E., Skladany L., Skrypnyk I., Song M. J., Sookoian S., Sridharan K., Stefan N., Stine J. G., Stratakis N., Sheriff D. S., Sundaram S. S., Svegliati-Baroni G., Swain M. G., Tacke F., Taheri S., Tan S. -S., Tapper E. B., Targher G., Tcaciuc E., Thiele M., Tiniakos D., Tolmane I., Torre A., Torres E. A., Treeprasertsuk S., Trenell M., Turcan S., Turcanu A., Valantinas J., van Kleef L. A., Velarde Ruiz Velasco J. A., Vesterhus M., Vilar-Gomez E., Waked I., Wattacheril J., Wedemeyer H., Wilkins F., Willemse J., Wong R. J., Yilmaz Y., Yki-Jarvinen H., Yu M. -L., Yumuk V., Zeybel M., Zheng K. I., and Zheng M. -H.
Abstract: Background & aims: An estimated 38% of adults worldwide have non-alcoholic fatty liver disease (NAFLD). From individual impacts to widespread public health and economic consequences, the implications of this disease are profound. This study aimed to develop an aligned, prioritised fatty liver disease research agenda for the global health community. Methods: Nine co-chairs drafted initial research priorities, subsequently reviewed by 40 core authors and debated during a three-day in-person meeting. Following a Delphi methodology, over two rounds, a large panel (R1 n = 344, R2 n = 288) reviewed the priorities, via Qualtrics XM, indicating agreement using a four-point Likert-scale and providing written feedback. The core group revised the draft priorities between rounds. In R2, panellists also ranked the priorities within six domains: epidemiology, models of care, treatment and care, education and awareness, patient and community perspectives, and leadership and public health policy. Results: The consensus-built fatty liver disease research agenda encompasses 28 priorities. The mean percentage of ‘agree’ responses increased from 78.3 in R1 to 81.1 in R2. Five priorities received unanimous combined agreement (‘agree’ + ‘somewhat agree’); the remaining 23 priorities had >90% combined agreement. While all but one of the priorities exhibited at least a super-majority of agreement (>66.7% ‘agree’), 13 priorities had [removed]90% combined agreement. Conclusions: Adopting this multidisciplinary consensus-built research priorities agenda can deliver a step-change in addressing fatty liver disease, mitigating against its individual and societal harms and proactively altering its natural history through prevention, identification, treatment, and care. This agenda should catalyse the global health community's efforts to advance and accelerate responses to this widespread and fast-growing public health threat. Impact and implications: An estimated 38% of adults and 13% o
Published: 2023

2. Advancing the global public health agenda for NAFLD: a consensus statement

Author: Lazarus, J.V. Mark, H.E. Anstee, Q.M. Arab, J.P. Batterham, R.L. Castera, L. Cortez-Pinto, H. Crespo, J. Cusi, K. Dirac, M.A. Francque, S. George, J. Hagström, H. Huang, T.T.-K. Ismail, M.H. Kautz, A. Sarin, S.K. Loomba, R. Miller, V. Newsome, P.N. Ninburg, M. Ocama, P. Ratziu, V. Rinella, M. Romero, D. Romero-Gómez, M. Schattenberg, J.M. Tsochatzis, E.A. Valenti, L. Wong, V.W.-S. Yilmaz, Y. Younossi, Z.M. Zelber-Sagi, S. Åberg, F. Adams, L. Khatry, M.S.A. Naamani, K.A. Murillo, O.A. Allen, A.M. Alnaser, F. Alqahtani, S.A. Alswat, K. Alvaro, D. Andrade, R.J. Arrese, M. Awuku, Y.A. Ayesha, M. Baatarkhuu, O. Bakieva, S. Basu, R. Bataller, R. Bedri, S. Bosi, E. Bourliere, M. Bruha, R. Bugianesi, E. Burra, P. Buti, M. Byrne, C.D. Calleja, J.L. Carrieri, P. Carter, F. Fernandez, M.I.C. Castillo-Lopez, G. Castro-Narro, G.E. Chan, H.L.Y. Chan, W.-K. Chang, Y. Colombo, M. Coppell, K.J. Corey, K. Craxi, A. Cryer, D. Dassanayake, A. Martins, A.A.S. de Ledinghen, V. DelPrato, S. Demaio, A. Desalegn, H. Dillon, J. Duseja, A. Dorairaj, P. Ekstedt, M. El Kassas, M. Elsanousi, O.M. Esmat, G. Fan, J.-G. Farpour-Lambert, N. Flisiak, R. Fouad, Y. Fuchs, M. Gani, R.A. Gerber, L. Ghazinyan, H. Gheorghe, L. Goh, G.B.-B. Grønbæk, H. Gulnara, A. Hamid, S. Hebditch, V. Hickman, I.J. Hocking, S.L. Hunyady, B. Idilman, R. Isakov, V.A. Jamal, M.H. Jepsen, P. Iskandar, N.J. Song, M.J. Sudhamshu, K.C. Kakizaki, S. Kalamitsis, G. Kanwal, F. Kao, J.-H. Kaplan, L. Kawaguchi, T. Khader, Y. Kim, S.U. Kodjoh, N. Koek, G. Koike, K. Komas, N.P. Korenjak, M. Kugelmas, M. Labidi, A. Lange, N.F. Lavine, J.E. Lazo, M. Lee, N. Lesmana, C.R.A. Liu, C.-J. Long, M.T. Lopez-Jaramillo, P. Malekzadeh, R. Mahtab, M.A. Marchesini, G. Marinho, R. Vázquez, S.E.M. Mateva, L. Nlombi, C.M. Melin, P. Mikolasevic, I. Milovanovic, T. Musso, C. Nakajima, A. Nava, E. Nersesov, A.V. Nikolova, D. Norris, S. Novak, K. Oben, J. Ong, J.P. Onyekwere, C. Papatheodoridis, G. Paruk, I. Patel, K. Macedo, M.P. Penha-Gonçalves, C. Figueroa, M.P. Hofmann, W.P. Petta, S. de Oliveira, C.P.M.S. Puri, P. Pan, C.Q. Rac, M. Ralston, J. Ramji, A. Razavi, H. Alvares-da-Silva, M.R. Roberts, S. Roden, M. Rose, T. Rouabhia, S. Rovere-Querini, P. Rowe, I.A. Sadirova, S. Salupere, R. Saparbu, T. Sayegh, R. Sebastiani, G. Seki, Y. Selmo, J. Serme, A.K. Shaw, J.E. Shenoy, T. Sheron, N. Shibolet, O. Silva, M. Skrypnyk, I. Socha, P. Soriano, J. Spearman, C.W. Sridharan, K. Suárez, J.J. Sheriff, D.S. Sung, K.-C. Swain, M. Tacke, F. Taheri, S. Tan, S.-S. Tapper, E.B. Yki-Järvinen, H. Thiele, M. Shawa, I.T. Tolmane, I. Torres, E.A. Trauner, M. Treeprasertsuk, S. Turcanu, A. Valantinas, J. Vesterhus, M. Waked, I. Wild, S.H. Willemse, J. Wong, R.J. Xanthakos, S. Young, D.Y. Yu, M.-L. Zheng, K.I. Zeybel, M. Zheng, M.-H. the NAFLD Consensus Consortium
Abstract: Non-alcoholic fatty liver disease (NAFLD) is a potentially serious liver disease that affects approximately one-quarter of the global adult population, causing a substantial burden of ill health with wide-ranging social and economic implications. It is a multisystem disease and is considered the hepatic component of metabolic syndrome. Unlike other highly prevalent conditions, NAFLD has received little attention from the global public health community. Health system and public health responses to NAFLD have been weak and fragmented, and, despite its pervasiveness, NAFLD is largely unknown outside hepatology and gastroenterology. There is only a nascent global public health movement addressing NAFLD, and the disease is absent from nearly all national and international strategies and policies for non-communicable diseases, including obesity. In this global Delphi study, a multidisciplinary group of experts developed consensus statements and recommendations, which a larger group of collaborators reviewed over three rounds until consensus was achieved. The resulting consensus statements and recommendations address a broad range of topics — from epidemiology, awareness, care and treatment to public health policies and leadership — that have general relevance for policy-makers, health-care practitioners, civil society groups, research institutions and affected populations. These recommendations should provide a strong foundation for a comprehensive public health response to NAFLD. © 2021, Springer Nature Limited.
Published: 2022

3. The present and future disease burden of hepatitis C virus infections with todayʼs treatment paradigm – volume 3

Author: Sibley, A., Han, K. H., Abourached, A., Lesmana, L. A., Makara, M., Jafri, W., Salupere, R., Assiri, A. M., Goldis, A., Abaalkhail, F., Abbas, Z., Abdou, A., Al Braiki, F., Al Hosani, F., Al Jaberi, K., Al Khatry, M., Al Mulla, M. A., Al Quraishi, H., Al Rifai, A., Al Serkal, Y., Alam, A., Alavian, S. M., Alashgar, H. I., Alawadhi, S., Al-Dabal, L., Aldins, P., Alfaleh, F. Z., Alghamdi, A. S., Al-Hakeem, R., Aljumah, A. A., Almessabi, A., Alqutub, A. N., Alswat, K. A., Altraif, I., Alzaabi, M., Andrea, N., Babatin, M. A., Baqir, A., Barakat, M. T., Bergmann, O. M., Bizri, A. R., Blach, S., Chaudhry, A., Choi, M. S., Diab, T., Djauzi, S., El Hassan, E. S., El Khoury, S., Estes, C., Fakhry, S., Farooqi, J. I., Fridjonsdottir, H., Gani, R. A., Ghafoor Khan, A., Gheorghe, L., Gottfredsson, M., Gregorcic, S., Gunter, J., Hajarizadeh, B., Hamid, S., Hasan, I., Hashim, A., Horvath, G., Hunyady, B., Husni, R., Jeruma, A., Jonasson, J. G., Karlsdottir, B., Kim, D. Y., Kim, Y. S., Koutoubi, Z., Liakina, V., Lim, Y. S., Löve, A., Maimets, M., Malekzadeh, R., Matičič, M., Memon, M. S., Merat, S., Mokhbat, J. E., Mourad, F. H., Muljono, D. H., Nawaz, A., Nugrahini, N., Olafsson, S., Priohutomo, S., Qureshi, H., Rassam, P., Razavi, H., Razavi-Shearer, D., Razavi-Shearer, K., Rozentale, B., Sadik, M., Saeed, K., Salamat, A., Sanai, F. M., Sanityoso Sulaiman, A., Sayegh, R. A., Sharara, A. I., Siddiq, M., Siddiqui, A. M., Sigmundsdottir, G., Sigurdardottir, B., Speiciene, D., Sulaiman, A., Sultan, M. A., Taha, M., Tanaka, J., Tarifi, H., Tayyab, G., Tolmane, I., Ud din, M., Umar, M., Valantinas, J., Videčnik-Zorman, J., Yaghi, C., Yunihastuti, E., Yusuf, M. A., Zuberi, B. F., and Schmelzer, J. D.
Published: 2015
Full Text: View/download PDF

4. Historical epidemiology of hepatitis C virus (HCV) in select countries – volume 3

Author: Liakina, V., Hamid, S., Tanaka, J., Olafsson, S., Sharara, A. I., Alavian, S. M., Gheorghe, L., El Hassan, E. S., Abaalkhail, F., Abbas, Z., Abdou, A., Abourached, A., Al Braiki, F., Al Hosani, F., Al Jaberi, K., Al Khatry, M., Al Mulla, M. A., Al Quraishi, H., Al Rifai, A., Al Serkal, Y., Alam, A., Alashgar, H. I., Alawadhi, S., Al-Dabal, L., Aldins, P., Alfaleh, F. Z., Alghamdi, A. S., Al-Hakeem, R., Aljumah, A. A., Almessabi, A., Alqutub, A. N., Alswat, K. A., Altraif, I., Alzaabi, M., Andrea, N., Assiri, A. M., Babatin, M. A., Baqir, A., Barakat, M. T., Bergmann, O. M., Bizri, A. R., Blach, S., Chaudhry, A., Choi, M. S., Diab, T., Djauzi, S., El Khoury, S., Estes, C., Fakhry, S., Farooqi, J. I., Fridjonsdottir, H., Gani, R. A., Ghafoor Khan, A., Goldis, A., Gottfredsson, M., Gregorcic, S., Hajarizadeh, B., Han, K. H., Hasan, I., Hashim, A., Horvath, G., Hunyady, B., Husni, R., Jafri, W., Jeruma, A., Jonasson, J. G., Karlsdottir, B., Kim, D. Y., Kim, Y. S., Koutoubi, Z., Lesmana, L. A., Lim, Y. S., Löve, A., Maimets, M., Makara, M., Malekzadeh, R., Matičič, M., Memon, M. S., Merat, S., Mokhbat, J. E., Mourad, F. H., Muljono, D. H., Nawaz, A., Nugrahini, N., Priohutomo, S., Qureshi, H., Rassam, P., Razavi, H., Razavi-Shearer, D., Razavi-Shearer, K., Rozentale, B., Sadik, M., Saeed, K., Salamat, A., Salupere, R., Sanai, F. M., Sanityoso Sulaiman, A., Sayegh, R. A., Schmelzer, J. D., Sibley, A., Siddiq, M., Siddiqui, A. M., Sigmundsdottir, G., Sigurdardottir, B., Speiciene, D., Sulaiman, A., Sultan, M. A., Taha, M., Tarifi, H., Tayyab, G., Tolmane, I., Ud din, M., Umar, M., Valantinas, J., Videčnik-Zorman, J., Yaghi, C., Yunihastuti, E., Yusuf, M. A., Zuberi, B. F., and Gunter, J.
Published: 2015
Full Text: View/download PDF

5. Strategies to manage hepatitis C virus infection disease burden – volume 3

Author: Alfaleh, F. Z., Nugrahini, N., Matičič, M., Tolmane, I., Alzaabi, M., Hajarizadeh, B., Valantinas, J., Kim, D. Y., Hunyady, B., Abaalkhail, F., Abbas, Z., Abdou, A., Abourached, A., Al Braiki, F., Al Hosani, F., Al Jaberi, K., Al Khatry, M., Al Mulla, M. A., Al Quraishi, H., Al Rifai, A., Al Serkal, Y., Alam, A., Alashgar, H. I., Alavian, S. M., Alawadhi, S., Al-Dabal, L., Aldins, P., Alghamdi, A. S., Al-Hakeem, R., Aljumah, A. A., Almessabi, A., Alqutub, A. N., Alswat, K. A., Altraif, I., Andrea, N., Assiri, A. M., Babatin, M. A., Baqir, A., Barakat, M. T., Bergmann, O. M., Bizri, A. R., Chaudhry, A., Choi, M. S., Diab, T., Djauzi, S., El Hassan, E. S., El Khoury, S., Estes, C., Fakhry, S., Farooqi, J. I., Fridjonsdottir, H., Gani, R. A., Ghafoor Khan, A., Gheorghe, L., Goldis, A., Gottfredsson, M., Gregorcic, S., Gunter, J., Hamid, S., Han, K. H., Hasan, I., Hashim, A., Horvath, G., Husni, R., Jafri, W., Jeruma, A., Jonasson, J. G., Karlsdottir, B., Kim, Y. S., Koutoubi, Z., Lesmana, L. A., Liakina, V., Lim, Y. S., Löve, A., Maimets, M., Makara, M., Malekzadeh, R., Memon, M. S., Merat, S., Mokhbat, J. E., Mourad, F. H., Muljono, D. H., Nawaz, A., Olafsson, S., Priohutomo, S., Qureshi, H., Rassam, P., Razavi, H., Razavi-Shearer, D., Razavi-Shearer, K., Rozentale, B., Sadik, M., Saeed, K., Salamat, A., Salupere, R., Sanai, F. M., Sanityoso Sulaiman, A., Sayegh, R. A., Schmelzer, J. D., Sharara, A. I., Sibley, A., Siddiq, M., Siddiqui, A. M., Sigmundsdottir, G., Sigurdardottir, B., Speiciene, D., Sulaiman, A., Sultan, M. A., Taha, M., Tanaka, J., Tarifi, H., Tayyab, G., Ud din, M., Umar, M., Videčnik-Zorman, J., Yaghi, C., Yunihastuti, E., Yusuf, M. A., Zuberi, B. F., and Blach, S.
Published: 2015
Full Text: View/download PDF

6. The case for simplifying and using absolute targets for viral hepatitis elimination goals

Author: Razavi, H. Blach, S. Razavi-Shearer, D. Abaalkhail, F. Abbas, Z. Abdallah, A. Abrao Ferreira, P. Abu Raddad, L.J. Adda, D. Agarwal, K. Aghemo, A. Ahmed, A. Al-Busafi, S.A. Al-hamoudi, W. Al-Kaabi, S. Al-Romaihi, H. Aljarallah, B. AlNaamani, K. Alqahtani, S. Alswat, K. Altraif, I. Asselah, T. Bacon, B. Bessone, F. Bizri, A.R. Block, T. Bonino, F. Brandão-Mello, C.E. Brown, K. Bruggmann, P. Brunetto, M.R. Buti, M. Cabezas, J. Calleja, J.L. Castro Batänjer, E. Chan, H.L.-Y. Chang, H. Chen, C.-J. Christensen, P.B. Chuang, W.-L. Cisneros, L. Cohen, C. Colombo, M. Conway, B. Cooper, C. Craxi, A. Crespo, J. Croes, E. Cryer, D. Cupertino de Barros, F.P. Derbala, M. Dillon, J. Doss, W. Dou, X. Doyle, J. Duberg, A.-S. Dugan, E. Dunn, R. Dusheiko, G. El Khayat, H. El-Sayed, M.H. Eshraghian, A. Esmat, G. Esteban Mur, R. Ezzat, S. Falconer, K. Fassio, E. Ferrinho, P. Flamm, S. Flisiak, R. Foster, G. Fung, J. García-Samaniego, J. Gish, R.G. Gonçales, F. Halota, W. Hamoudi, W. Hassany, M. Hatzakis, A. Hay, S. Himatt, S. Hoepelman, I.M. Hsu, Y.-C. Hui, Y.T. Hunyady, B. Jacobson, I. Janjua, N. Janssen, H. Jarcuska, P. Kabagambe, K. Kanto, T. Kao, J.-H. Kaymakoglu, S. Kershenobich, D. Khamis, F. Kim, D.J. Kim, D.Y. Kondili, L.A. Kottilil, S. Kramvis, A. Kugelmas, M. Kurosaki, M. Lacombe, K. Lagging, M. Lao, W.-C. Lavanchy, D. Lazarus, J.V. Lee, A. Lee, S.S. Levy, M. Liakina, V. Lim, Y.-S. Liu, S. Maddrey, W. Malekzadeh, R. Marinho, R.T. Mathur, P. Maticic, M. Mendes Correa, M.C. Mera, J. Merat, S. Mogawer, S. Mohamed, R. Muellhaupt, B. Muljono, D. Mostafa, I. Nahum, M.S. Nawaz, A. Negro, F. Ninburg, M. Ning, Q. Ntiri- Reid, B. Nymadawa, P. Oevrehus, A. Ormeci, N. Orrego, M. Osman, A. Oyunsuren, T. Pan, C. Papaevangelou, V. Papatheodoridis, G. Popping, S. Prasad, P. Prithiviputh, R. Qureshi, H. Ramji, A. Razavi-Shearer, K. Reddy, R. Remak, W. Richter, C. Ridruejo, E. Robaeys, G. Roberts, S. Roberts, L. Roudot-Thoraval, F. Saab, S. Said, S. Salamat, A. Sanai, F. Sanchez-Avila, J.F. Schiff, E. Schinazi, R. Sebastiani, G. Seguin-Devaux, C. Shanmugam, R.P. Sharara, A. Shilton, S. Shouval, D. Sievert, W. Simonova, M. Sohrabpour, A.A. Sonderup, M. Soza, A. Wendy Spearman, C. Steinfurth, N. Sulkowski, M. Tan, S.-S. Tanaka, J. Tashi, D. Thein, H.-H. Thompson, P. Tolmane, I. Toy, M. Valantinas, J. Van de Vijver, D. Vélez-Möller, P. Vince, A. Waked, I. Wang, S. Wedemeyer, H. Wong, V. Xie, Q. Yamada, S. Yang, H.-I. Yesmembetov, K. Yilmaz, Y. Younossi, Z. Yu, M.-L. Yuen, M.-F. Yurdaydin, C. Yusuf, A. Zekry, A. Zeuzem, S. Polaris Observatory Collaborators
Subjects: digestive system diseases
Abstract: The 69th World Health Assembly endorsed the Global Health Sector Strategy for Viral Hepatitis, embracing a goal to eliminate hepatitis infection as a public health threat by 2030. This was followed by the World Health Organization's (WHO) global targets for the care and management of hepatitis B virus (HBV) and hepatitis C virus (HCV) infections. These announcements and targets were important in raising awareness and calling for action; however, tracking countries’ progress towards these elimination goals has provided insights to the limitations of these targets. The existing targets compare a country's progress relative to its 2015 values, penalizing countries who started their programmes prior to 2015, countries with a young population, or countries with a low prevalence. We recommend that (1) WHO simplify the hepatitis elimination targets, (2) change to absolute targets and (3) allow countries to achieve these disease targets with their own service coverage initiatives that will have the maximum impact. The recommended targets are as follows: reduce HCV new chronic cases to ≤5 per 100 000, reduce HBV prevalence among 1-year-olds to ≤0.1%, reduce HBV and HCV mortality to ≤5 per 100 000, and demonstrate HBV and HCV year-to-year decrease in new HCV- and HBV-related HCC cases. The objective of our recommendations is not to lower expectations or diminish the hepatitis elimination standards, but to provide clearer targets that recognize the past and current elimination efforts by countries, help measure progress towards true elimination, and motivate other countries to follow suit. © 2020 John Wiley & Sons Ltd
Published: 2021

7. The case for simplifying and using absolute targets for viral hepatitis elimination goals.

Author: Razavi H., Blach S., Razavi-Shearer D., Abaalkhail F., Abbas Z., Abdallah A., Abrao Ferreira P., Abu Raddad L.J., Adda D., Agarwal K., Aghemo A., Ahmed A., Al-Busafi S.A., Al-hamoudi W., Al-Kaabi S., Al-Romaihi H., Aljarallah B., AlNaamani K., Alqahtani S., Alswat K., Altraif I., Asselah T., Bacon B., Bessone F., Bizri A.R., Block T., Bonino F., Brandao-Mello C.E., Brown K., Bruggmann P., Brunetto M.R., Buti M., Cabezas J., Calleja J.L., Castro Batanjer E., Chan H.L.-Y., Chang H., Chen C.-J., Christensen P.B., Chuang W.-L., Cisneros L., Cohen C., Colombo M., Conway B., Cooper C., Craxi A., Crespo J., Croes E., Cryer D., Cupertino de Barros F.P., Derbala M., Dillon J., Doss W., Dou X., Doyle J., Duberg A.-S., Dugan E., Dunn R., Dusheiko G., El Khayat H., El-Sayed M.H., Eshraghian A., Esmat G., Esteban Mur R., Ezzat S., Falconer K., Fassio E., Ferrinho P., Flamm S., Flisiak R., Foster G., Fung J., Garcia-Samaniego J., Gish R.G., Goncales F., Halota W., Hamoudi W., Hassany M., Hatzakis A., Hay S., Himatt S., Hoepelman I.M., Hsu Y.-C., Hui Y.T., Hunyady B., Jacobson I., Janjua N., Janssen H., Jarcuska P., Kabagambe K., Kanto T., Kao J.-H., Kaymakoglu S., Kershenobich D., Khamis F., Kim D.J., Kim D.Y., Kondili L.A., Kottilil S., Kramvis A., Kugelmas M., Kurosaki M., Lacombe K., Lagging M., Lao W.-C., Lavanchy D., Lazarus J.V., Lee A., Lee S.S., Levy M., Liakina V., Lim Y.-S., Liu S., Maddrey W., Malekzadeh R., Marinho R.T., Mathur P., Maticic M., Mendes Correa M.C., Mera J., Merat S., Mogawer S., Mohamed R., Muellhaupt B., Muljono D., Mostafa I., Nahum M.S., Nawaz A., Negro F., Ninburg M., Ning Q., Ntiri- Reid B., Nymadawa P., Oevrehus A., Ormeci N., Orrego M., Osman A., Oyunsuren T., Pan C., Papaevangelou V., Papatheodoridis G., Popping S., Prasad P., Prithiviputh R., Qureshi H., Ramji A., Razavi-Shearer K., Reddy R., Remak W., Richter C., Ridruejo E., Robaeys G., Roberts S., Roberts L., Roudot-Thoraval F., Saab S., Said S., Salamat A., Sanai F., Sanchez-Avila J.F., Schiff E., Schinazi R., Sebastiani G., Seguin-Devaux C., Shanmugam R.P., Sharara A., Shilton S., Shouval D., Sievert W., Simonova M., Sohrabpour A.A., Sonderup M., Soza A., Wendy Spearman C., Steinfurth N., Sulkowski M., Tan S.-S., Tanaka J., Tashi D., Thein H.-H., Thompson P., Tolmane I., Toy M., Valantinas J., Van de Vijver D., Velez-Moller P., Vince A., Waked I., Wang S., Wedemeyer H., Wong V., Xie Q., Yamada S., Yang H.-I., Yesmembetov K., Yilmaz Y., Younossi Z., Yu M.-L., Yuen M.-F., Yurdaydin C., Yusuf A., Zekry A., Zeuzem S., Razavi H., Blach S., Razavi-Shearer D., Abaalkhail F., Abbas Z., Abdallah A., Abrao Ferreira P., Abu Raddad L.J., Adda D., Agarwal K., Aghemo A., Ahmed A., Al-Busafi S.A., Al-hamoudi W., Al-Kaabi S., Al-Romaihi H., Aljarallah B., AlNaamani K., Alqahtani S., Alswat K., Altraif I., Asselah T., Bacon B., Bessone F., Bizri A.R., Block T., Bonino F., Brandao-Mello C.E., Brown K., Bruggmann P., Brunetto M.R., Buti M., Cabezas J., Calleja J.L., Castro Batanjer E., Chan H.L.-Y., Chang H., Chen C.-J., Christensen P.B., Chuang W.-L., Cisneros L., Cohen C., Colombo M., Conway B., Cooper C., Craxi A., Crespo J., Croes E., Cryer D., Cupertino de Barros F.P., Derbala M., Dillon J., Doss W., Dou X., Doyle J., Duberg A.-S., Dugan E., Dunn R., Dusheiko G., El Khayat H., El-Sayed M.H., Eshraghian A., Esmat G., Esteban Mur R., Ezzat S., Falconer K., Fassio E., Ferrinho P., Flamm S., Flisiak R., Foster G., Fung J., Garcia-Samaniego J., Gish R.G., Goncales F., Halota W., Hamoudi W., Hassany M., Hatzakis A., Hay S., Himatt S., Hoepelman I.M., Hsu Y.-C., Hui Y.T., Hunyady B., Jacobson I., Janjua N., Janssen H., Jarcuska P., Kabagambe K., Kanto T., Kao J.-H., Kaymakoglu S., Kershenobich D., Khamis F., Kim D.J., Kim D.Y., Kondili L.A., Kottilil S., Kramvis A., Kugelmas M., Kurosaki M., Lacombe K., Lagging M., Lao W.-C., Lavanchy D., Lazarus J.V., Lee A., Lee S.S., Levy M., Liakina V., Lim Y.-S., Liu S., Maddrey W., Malekzadeh R., Marinho R.T., Mathur P., Maticic M., Mendes Correa M.C., Mera J., Merat S., Mogawer S., Mohamed R., Muellhaupt B., Muljono D., Mostafa I., Nahum M.S., Nawaz A., Negro F., Ninburg M., Ning Q., Ntiri- Reid B., Nymadawa P., Oevrehus A., Ormeci N., Orrego M., Osman A., Oyunsuren T., Pan C., Papaevangelou V., Papatheodoridis G., Popping S., Prasad P., Prithiviputh R., Qureshi H., Ramji A., Razavi-Shearer K., Reddy R., Remak W., Richter C., Ridruejo E., Robaeys G., Roberts S., Roberts L., Roudot-Thoraval F., Saab S., Said S., Salamat A., Sanai F., Sanchez-Avila J.F., Schiff E., Schinazi R., Sebastiani G., Seguin-Devaux C., Shanmugam R.P., Sharara A., Shilton S., Shouval D., Sievert W., Simonova M., Sohrabpour A.A., Sonderup M., Soza A., Wendy Spearman C., Steinfurth N., Sulkowski M., Tan S.-S., Tanaka J., Tashi D., Thein H.-H., Thompson P., Tolmane I., Toy M., Valantinas J., Van de Vijver D., Velez-Moller P., Vince A., Waked I., Wang S., Wedemeyer H., Wong V., Xie Q., Yamada S., Yang H.-I., Yesmembetov K., Yilmaz Y., Younossi Z., Yu M.-L., Yuen M.-F., Yurdaydin C., Yusuf A., Zekry A., and Zeuzem S.
Abstract: The 69th World Health Assembly endorsed the Global Health Sector Strategy for Viral Hepatitis, embracing a goal to eliminate hepatitis infection as a public health threat by 2030. This was followed by the World Health Organization's (WHO) global targets for the care and management of hepatitis B virus (HBV) and hepatitis C virus (HCV) infections. These announcements and targets were important in raising awareness and calling for action; however, tracking countries' progress towards these elimination goals has provided insights to the limitations of these targets. The existing targets compare a country's progress relative to its 2015 values, penalizing countries who started their programmes prior to 2015, countries with a young population, or countries with a low prevalence. We recommend that (1) WHO simplify the hepatitis elimination targets, (2) change to absolute targets and (3) allow countries to achieve these disease targets with their own service coverage initiatives that will have the maximum impact. The recommended targets are as follows: reduce HCV new chronic cases to <=5 per 100 000, reduce HBV prevalence among 1-year-olds to <=0.1%, reduce HBV and HCV mortality to <=5 per 100 000, and demonstrate HBV and HCV year-to-year decrease in new HCV- and HBV-related HCC cases. The objective of our recommendations is not to lower expectations or diminish the hepatitis elimination standards, but to provide clearer targets that recognize the past and current elimination efforts by countries, help measure progress towards true elimination, and motivate other countries to follow suit.Copyright © 2020 John Wiley & Sons Ltd
Published: 2021

8. BILIARY DUCT STENTING AND STENT PATENCY: WHO, HOW LONG, WHY?

Author: Dieninytė-Misiūnė, E, additional, Valantinas, J, additional, and Stanaitis, J, additional
Published: 2020
Full Text: View/download PDF

9. Acetazolamide inhibits stimulated feline liver and gallbladder bicarbonate secretion*

Author: NILSSON, B, VALANTINAS, J, HEDIN, L, FRIMAN, S, and SVANVIK, J
Published: 2002

10. LONG-TERM EFFICACY AND COST EFFECTIVENESS OF ENDOSCOPIC TREATMENT OF PANCREATIC PSEUDOCYSTS: PIGTAIL VS SELF EXPANDING METAL STENTS (SEMS)

Author: Dieninyte-Misiune, E, additional, Stanaitis, J, additional, and Valantinas, J, additional
Published: 2019
Full Text: View/download PDF

11. A186 EFFECT OF MILD ACUTE PANCREATITIS ON THE PORTAL VENOUS VELOCITIES

Author: Mickevicius, A, primary and Valantinas, J, additional
Published: 2019
Full Text: View/download PDF

12. Global prevalence and genotype distribution of hepatitis C virus infection in 2015: A modelling study

Author: Blach, S. Zeuzem, S. Manns, M. Altraif, I. Duberg, A.-S. Muljono, D.H. Waked, I. Alavian, S.M. Lee, M.-H. Negro, F. Abaalkhail, F. Abdou, A. Abdulla, M. Abou Rached, A. Aho, I. Akarca, U. Al Ghazzawi, I. Al Kaabi, S. Al Lawati, F. Al Namaani, K. Al Serkal, Y. Al-Busafi, S.A. Al-Dabal, L. Aleman, S. Alghamdi, A.S. Aljumah, A.A. Al-Romaihi, H.E. Andersson, M.I. Arendt, V. Arkkila, P. Assiri, A.M. Baatarkhuu, O. Bane, A. Ben-Ari, Z. Bergin, C. Bessone, F. Bihl, F. Bizri, A.R. Blachier, M. Blasco, A.J. Brandao Mello, C.E. Bruggmann, P. Brunton, C.R. Calinas, F. Chan, H.L.Y. Chaudhry, A. Cheinquer, H. Chen, C.-J. Chien, R.-N. Choi, M.S. Christensen, P.B. Chuang, W.-L. Chulanov, V. Cisneros, L. Clausen, M.R. Cramp, M.E. Craxi, A. Croes, E.A. Dalgard, O. Daruich, J.R. De Ledinghen, V. Dore, G.J. El-Sayed, M.H. Ergor, G. Esmat, G. Estes, C. Falconer, K. Farag, E. Ferraz, M.L.G. Ferreira, P.R. Flisiak, R. Frankova, S. Gamkrelidze, I. Gane, E. Garcia-Samaniego, J. Khan, A.G. Gountas, I. Goldis, A. Gottfredsson, M. Grebely, J. Gschwantler, M. Guimaraes Pessoa, M. Gunter, J. Hajarizadeh, B. Hajelssedig, O. Hamid, S. Hamoudi, W. Hatzakis, A. Himatt, S.M. Hofer, H. Hrstic, I. Hui, Y.-T. Hunyady, B. Idilman, R. Jafri, W. Jahis, R. Janjua, N.Z. Jarčuška, P. Jeruma, A. Jonasson, J.G. Kamel, Y. Kao, J.-H. Kaymakoglu, S. Kershenobich, D. Khamis, J. Kim, Y.S. Kondili, L. Koutoubi, Z. Krajden, M. Krarup, H. Lai, M.-S. Laleman, W. Lao, W.-C. Lavanchy, D. Lazaro, P. Leleu, H. Lesi, O. Lesmana, L.A. Li, M. Liakina, V. Lim, Y.-S. Luksic, B. Mahomed, A. Maimets, M. Makara, M. Malu, A.O. Marinho, R.T. Marotta, P. Mauss, S. Memon, M.S. Mendes Correa, M.C. Mendez-Sanchez, N. Merat, S. Metwally, A.M. Mohamed, R. Moreno, C. Mourad, F.H. Mullhaupt, B. Murphy, K. Nde, H. Njouom, R. Nonkovic, D. Norris, S. Obekpa, S. Oguche, S. Olafsson, S. Oltman, M. Omede, O. Omuemu, C. Opare-Sem, O. Ovrehus, A.L.H. Owusu-Ofori, S. Oyunsuren, T.S. Papatheodoridis, G. Pasini, K. Peltekian, K.M. Phillips, R.O. Pimenov, N. Poustchi, H. Prabdial-Sing, N. Qureshi, H. Ramji, A. Razavi-Shearer, D. Razavi-Shearer, K. Redae, B. Reesink, H.W. Ridruejo, E. Robbins, S. Roberts, L.R. Roberts, S.K. Rosenberg, W.M. Roudot-Thoraval, F. Ryder, S.D. Safadi, R. Sagalova, O. Salupere, R. Sanai, F.M. Sanchez Avila, J.F. Saraswat, V. Sarmento-Castro, R. Sarrazin, C. Schmelzer, J.D. Schreter, I. Seguin-Devaux, C. Shah, S.R. Sharara, A.I. Sharma, M. Shevaldin, A. Shiha, G.E. Sievert, W. Sonderup, M. Souliotis, K. Speiciene, D. Sperl, J. Starkel, P. Stauber, R.E. Stedman, C. Struck, D. Su, T.-H. Sypsa, V. Tan, S.-S. Tanaka, J. Thompson, A.J. Tolmane, I. Tomasiewicz, K. Valantinas, J. Van Damme, P. Van Der Meer, A.J. Van Thiel, I. Van Vlierberghe, H. Vince, A. Vogel, W. Wedemeyer, H. Weis, N. Wong, V.W.S. Yaghi, C. Yosry, A. Yuen, M.-F. Yunihastuti, E. Yusuf, A. Zuckerman, E. Razavi, H. The Polaris Observatory HCV Collaborators
Abstract: Background The 69th World Health Assembly approved the Global Health Sector Strategy to eliminate hepatitis C virus (HCV) infection by 2030, which can become a reality with the recent launch of direct acting antiviral therapies. Reliable disease burden estimates are required for national strategies. This analysis estimates the global prevalence of viraemic HCV at the end of 2015, an update of—and expansion on—the 2014 analysis, which reported 80 million (95% CI 64–103) viraemic infections in 2013. Methods We developed country-level disease burden models following a systematic review of HCV prevalence (number of studies, n=6754) and genotype (n=11 342) studies published after 2013. A Delphi process was used to gain country expert consensus and validate inputs. Published estimates alone were used for countries where expert panel meetings could not be scheduled. Global prevalence was estimated using regional averages for countries without data. Findings Models were built for 100 countries, 59 of which were approved by country experts, with the remaining 41 estimated using published data alone. The remaining countries had insufficient data to create a model. The global prevalence of viraemic HCV is estimated to be 1·0% (95% uncertainty interval 0·8–1·1) in 2015, corresponding to 71·1 million (62·5–79·4) viraemic infections. Genotypes 1 and 3 were the most common cause of infections (44% and 25%, respectively). Interpretation The global estimate of viraemic infections is lower than previous estimates, largely due to more recent (lower) prevalence estimates in Africa. Additionally, increased mortality due to liver-related causes and an ageing population may have contributed to a reduction in infections. Funding John C Martin Foundation. © 2017 Elsevier Ltd
Published: 2017

13. Hepatitis C virus prevalence and level of intervention required to achieve the WHO targets for elimination in the European Union by 2030: a modelling study

Author: Razavi, H. Robbins, S. Zeuzem, S. Negro, F. Buti, M. Duberg, A. Roudot-Thoraval, F. Craxi, A. Manns, M. Marinho, R.T. Hunyady, B. Colombo, M. Aleman, S. Antonov, K. Arkkila, P. Athanasakis, K. Blach, S. Blachier, M. Blasco, A.J. Calinas, F. Calleja, J.L. Christensen, P.B. Cramp, M.E. Croes, E. de Knegt, R.J. de Ledinghen, V. Delile, J.-M. Estes, C. Falconer, K. Färkkilä, M. Flisiak, R. Frankova, S. Gamkrelidze, I. García-Samaniego, J. Genov, J. Gerstoft, J. Gheorghe, L. Goldis, A. Gountas, I. Gregorčič, S. Gschwantler, M. Gunter, J. Halota, W. Harcouet, L. Hézode, C. Hoffmann, P. Horvath, G. Hrstic, I. Jarčuška, P. Jelev, D. Jeruma, A. Kåberg, M. Kieran, J. Kondili, L.A. Kotzev, I. Krarup, H. Kristian, P. Lagging, M. Laleman, W. Lázaro, P. Liakina, V. Lukšić, B. Maimets, M. Makara, M. Mateva, L. Maticic, M. Mennini, F.S. Mitova, R. Moreno, C. Mossong, J. Murphy, K. Nde, H. Nemecek, V. Nonkovic, D. Norris, S. Oltman, M. Øvrehus, A.L.H. Papatheodoridis, G. Pasini, K. Razavi-Shearer, D. Razavi-Shearer, K. Reesink, H.W. Reic, T. Rozentale, B. Ryder, S.D. Salupere, R. Sarmento-Castro, R. Sarrazin, C. Schmelzer, J.D. Schréter, I. Seguin-Devaux, C. Simojoki, K. Simonova, M. Smit, P.J. Souliotis, K. Speiciene, D. Sperl, J. Stärkel, P. Struck, D. Sypsa, V. Thornton, L. Tolmane, I. Tomasiewicz, K. Valantinas, J. Van Damme, P. van de Vijver, D. van der Meer, A.J. van Santen, D. Van Vlierberghe, H. Vandijck, D. Vella, S. Videčnik-Zorman, J. Vogel, W. Weis, N. Hatzakis, A. The European Union HCV Collaborators
Abstract: Background Hepatitis C virus (HCV) is a leading cause of liver-related morbidity and mortality worldwide. In the European Union (EU), treatment and cure of HCV with direct-acting antiviral therapies began in 2014. WHO targets are to achieve a 65% reduction in liver-related deaths, a 90% reduction of new viral hepatitis infections, and 90% of patients with viral hepatitis infections being diagnosed by 2030. This study assessed the prevalence of HCV in the EU and the level of intervention required to achieve WHO targets for HCV elimination. Methods We populated country Markov models for the 28 EU countries through a literature search of PubMed and Embase between Jan 1, 2000, and March 31, 2016, and a Delphi process to gain expert consensus and validate inputs. We aggregated country models to create a regional EU model. We used the EU model to forecast HCV disease progression (considering the effect of immigration) and developed a strategy to acehive WHO targets. We used weighted average sustained viral response rates and fibrosis restrictions to model the effect of current therapeutic guidelines. We used the EU model to forecast HCV disease progression (considering the effect of immigration) under current screening and therapeutic guidelines. Additionally, we back-calculated the total number of patients needing to be screened and treated to achieve WHO targets. Findings We estimated the number of viraemic HCV infections in 2015 to be 3 238 000 (95% uncertainty interval [UI] 2 106 000–3 795 000) of a total population of 509 868 000 in the EU, equating to a prevalence of viraemic HCV of 0·64% (95% UI 0·41–0·74). We estimated that 1 180 000 (95% UI 1 003 000–1 357 000) people were diagnosed with viraemia (36·4%), 150 000 (12 000–180 000) were treated (4·6% of the total infected population or 12·7% of the diagnosed population), 133 000 (106 000–160 000) were cured (4·1%), and 57 900 (43 900–67 300) were newly infected (1·8%) in 2015. Additionally, 30 400 (26 600–42 500) HCV-positive immigrants entered the EU. To achieve WHO targets, unrestricted treatment needs to increase from 150 000 patients in 2015 to 187 000 patients in 2025 and diagnosis needs to increase from 88 800 new cases annually in 2015 to 180 000 in 2025. Interpretation Given its advanced health-care infrastructure, the EU is uniquely poised to eliminate HCV; however, expansion of screening programmes is essential to increase treatment to achieve the WHO targets. A united effort, grounded in sound epidemiological evidence, will also be necessary. Funding Gilead Sciences. © 2017 Elsevier Ltd
Published: 2017

14. Global prevalence and genotype distribution of hepatitis C virus infection in 2015: A modelling study.

Author: Farag E., De Ledinghen V., Dore G.J., Papatheodoridis G., Pasini K., Peltekian K.M., Phillips R.O., Pimenov N., Poustchi H., Prabdial-Sing N., Qureshi H., Ramji A., Razavi-Shearer D., Razavi-Shearer K., Redae B., Reesink H.W., Ridruejo E., Robbins S., Roberts L.R., Roberts S.K., Rosenberg W.M., Roudot-Thoraval F., Ryder S.D., Safadi R., Sagalova O., Salupere R., Sanai F.M., Sanchez Avila J.F., Saraswat V., Sarmento-Castro R., Sarrazin C., Schmelzer J.D., Schreter I., Seguin-Devaux C., Shah S.R., Sharara A.I., Sharma M., Shevaldin A., Shiha G.E., Sonderup M., Souliotis K., Speiciene D., Sperl J., Starkel P., Stauber R.E., Stedman C., Struck D., Su T.-H., Sypsa V., Tan S.-S., Tanaka J., Thompson A.J., Tolmane I., Tomasiewicz K., Valantinas J., Van Damme P., Van Der Meer A.J., Van Thiel I., Van Vlierberghe H., Vince A., Vogel W., Wedemeyer H., Weis N., Wong V.W.S., Yaghi C., Yosry A., Yuen M.-F., Yunihastuti E., Yusuf A., Zuckerman E., Razavi H., Sievert W., Blach S., Zeuzem S., Manns M., Altraif I., Duberg A.-S., Muljono D.H., Waked I., Alavian S.M., Lee M.-H., Negro F., Abaalkhail F., Abdou A., Abdulla M., Abou Rached A., Aho I., Akarca U., Al Ghazzawi I., Al Kaabi S., Al Lawati F., Al Namaani K., Al Serkal Y., Al-Busafi S.A., Al-Dabal L., Aleman S., Alghamdi A.S., Aljumah A.A., Al-Romaihi H.E., Andersson M.I., Arendt V., Arkkila P., Assiri A.M., Baatarkhuu O., Bane A., Ben-Ari Z., Bergin C., Bessone F., Bihl F., Bizri A.R., Blachier M., Blasco A.J., Brandao Mello C.E., Bruggmann P., Brunton C.R., Calinas F., Chan H.L.Y., Chaudhry A., Cheinquer H., Chen C.-J., Chien R.-N., Choi M.S., Christensen P.B., Chuang W.-L., Chulanov V., Cisneros L., Clausen M.R., Cramp M.E., Craxi A., Croes E.A., Dalgard O., Daruich J.R., El-Sayed M.H., Ergor G., Esmat G., Estes C., Falconer K., Ferraz M.L.G., Ferreira P.R., Flisiak R., Frankova S., Gamkrelidze I., Gane E., Garcia-Samaniego J., Khan A.G., Gountas I., Goldis A., Gottfredsson M., Grebely J., Gschwantler M., Guimaraes Pessoa M., Gunter J., Hajarizadeh B., Hajelssedig O., Hamid S., Hamoudi W., Hatzakis A., Himatt S.M., Hofer H., Hrstic I., Hui Y.-T., Hunyady B., Idilman R., Jafri W., Jahis R., Janjua N.Z., Jarcuska P., Jeruma A., Jonasson J.G., Kamel Y., Kao J.-H., Kaymakoglu S., Kershenobich D., Khamis J., Kim Y.S., Kondili L., Koutoubi Z., Krajden M., Krarup H., Lai M.-S., Laleman W., Lao W.-C., Lavanchy D., Lazaro P., Leleu H., Lesi O., Lesmana L.A., Li M., Liakina V., Lim Y.-S., Luksic B., Mahomed A., Maimets M., Makara M., Malu A.O., Marinho R.T., Marotta P., Mauss S., Memon M.S., Mendes Correa M.C., Mendez-Sanchez N., Merat S., Metwally A.M., Mohamed R., Moreno C., Mourad F.H., Mullhaupt B., Murphy K., Nde H., Njouom R., Nonkovic D., Norris S., Obekpa S., Oguche S., Olafsson S., Oltman M., Omede O., Omuemu C., Opare-Sem O., Ovrehus A.L.H., Owusu-Ofori S., Oyunsuren T.S., Farag E., De Ledinghen V., Dore G.J., Papatheodoridis G., Pasini K., Peltekian K.M., Phillips R.O., Pimenov N., Poustchi H., Prabdial-Sing N., Qureshi H., Ramji A., Razavi-Shearer D., Razavi-Shearer K., Redae B., Reesink H.W., Ridruejo E., Robbins S., Roberts L.R., Roberts S.K., Rosenberg W.M., Roudot-Thoraval F., Ryder S.D., Safadi R., Sagalova O., Salupere R., Sanai F.M., Sanchez Avila J.F., Saraswat V., Sarmento-Castro R., Sarrazin C., Schmelzer J.D., Schreter I., Seguin-Devaux C., Shah S.R., Sharara A.I., Sharma M., Shevaldin A., Shiha G.E., Sonderup M., Souliotis K., Speiciene D., Sperl J., Starkel P., Stauber R.E., Stedman C., Struck D., Su T.-H., Sypsa V., Tan S.-S., Tanaka J., Thompson A.J., Tolmane I., Tomasiewicz K., Valantinas J., Van Damme P., Van Der Meer A.J., Van Thiel I., Van Vlierberghe H., Vince A., Vogel W., Wedemeyer H., Weis N., Wong V.W.S., Yaghi C., Yosry A., Yuen M.-F., Yunihastuti E., Yusuf A., Zuckerman E., Razavi H., Sievert W., Blach S., Zeuzem S., Manns M., Altraif I., Duberg A.-S., Muljono D.H., Waked I., Alavian S.M., Lee M.-H., Negro F., Abaalkhail F., Abdou A., Abdulla M., Abou Rached A., Aho I., Akarca U., Al Ghazzawi I., Al Kaabi S., Al Lawati F., Al Namaani K., Al Serkal Y., Al-Busafi S.A., Al-Dabal L., Aleman S., Alghamdi A.S., Aljumah A.A., Al-Romaihi H.E., Andersson M.I., Arendt V., Arkkila P., Assiri A.M., Baatarkhuu O., Bane A., Ben-Ari Z., Bergin C., Bessone F., Bihl F., Bizri A.R., Blachier M., Blasco A.J., Brandao Mello C.E., Bruggmann P., Brunton C.R., Calinas F., Chan H.L.Y., Chaudhry A., Cheinquer H., Chen C.-J., Chien R.-N., Choi M.S., Christensen P.B., Chuang W.-L., Chulanov V., Cisneros L., Clausen M.R., Cramp M.E., Craxi A., Croes E.A., Dalgard O., Daruich J.R., El-Sayed M.H., Ergor G., Esmat G., Estes C., Falconer K., Ferraz M.L.G., Ferreira P.R., Flisiak R., Frankova S., Gamkrelidze I., Gane E., Garcia-Samaniego J., Khan A.G., Gountas I., Goldis A., Gottfredsson M., Grebely J., Gschwantler M., Guimaraes Pessoa M., Gunter J., Hajarizadeh B., Hajelssedig O., Hamid S., Hamoudi W., Hatzakis A., Himatt S.M., Hofer H., Hrstic I., Hui Y.-T., Hunyady B., Idilman R., Jafri W., Jahis R., Janjua N.Z., Jarcuska P., Jeruma A., Jonasson J.G., Kamel Y., Kao J.-H., Kaymakoglu S., Kershenobich D., Khamis J., Kim Y.S., Kondili L., Koutoubi Z., Krajden M., Krarup H., Lai M.-S., Laleman W., Lao W.-C., Lavanchy D., Lazaro P., Leleu H., Lesi O., Lesmana L.A., Li M., Liakina V., Lim Y.-S., Luksic B., Mahomed A., Maimets M., Makara M., Malu A.O., Marinho R.T., Marotta P., Mauss S., Memon M.S., Mendes Correa M.C., Mendez-Sanchez N., Merat S., Metwally A.M., Mohamed R., Moreno C., Mourad F.H., Mullhaupt B., Murphy K., Nde H., Njouom R., Nonkovic D., Norris S., Obekpa S., Oguche S., Olafsson S., Oltman M., Omede O., Omuemu C., Opare-Sem O., Ovrehus A.L.H., Owusu-Ofori S., and Oyunsuren T.S.
Abstract: Background The 69th World Health Assembly approved the Global Health Sector Strategy to eliminate hepatitis C virus (HCV) infection by 2030, which can become a reality with the recent launch of direct acting antiviral therapies. Reliable disease burden estimates are required for national strategies. This analysis estimates the global prevalence of viraemic HCV at the end of 2015, an update of-and expansion on-the 2014 analysis, which reported 80 million (95% CI 64-103) viraemic infections in 2013. Methods We developed country-level disease burden models following a systematic review of HCV prevalence (number of studies, n=6754) and genotype (n=11 342) studies published after 2013. A Delphi process was used to gain country expert consensus and validate inputs. Published estimates alone were used for countries where expert panel meetings could not be scheduled. Global prevalence was estimated using regional averages for countries without data. Findings Models were built for 100 countries, 59 of which were approved by country experts, with the remaining 41 estimated using published data alone. The remaining countries had insufficient data to create a model. The global prevalence of viraemic HCV is estimated to be 1.0% (95% uncertainty interval 0.8-1.1) in 2015, corresponding to 71.1 million (62.5-79.4) viraemic infections. Genotypes 1 and 3 were the most common cause of infections (44% and 25%, respectively). Interpretation The global estimate of viraemic infections is lower than previous estimates, largely due to more recent (lower) prevalence estimates in Africa. Additionally, increased mortality due to liver-related causes and an ageing population may have contributed to a reduction in infections. Funding John C Martin Foundation.Copyright © 2017 Elsevier Ltd
Published: 2017

15. Expression Levels of the Uridine-Cytidine Kinase Like-1 Protein As a Novel Prognostic Factor for Hepatitis C VirusAssociated Hepatocellular Carcinomas

Author: Buivydiene, A., primary, Liakina, V., additional, Valantinas, J., additional, Norkuniene, J., additional, Mockiene, E., additional, Jokubauskiene, S., additional, Smaliukiene, R., additional, Jancoriene, L., additional, Kovalevska, L., additional, and Kashuba, E., additional
Published: 2017
Full Text: View/download PDF

16. Association of the prevalence and grade of steatosis in patients with chronic hepatitis C with the host and viral factors

Author: Valentina Liakina, Speiciené D, Irnius A, Semuchiniené T, and Valantinas J
Subjects: Adult, Aged, 80 and over, Liver Cirrhosis, Male, Adolescent, Alcohol Drinking, Age Factors, Lithuania, Hepacivirus, Hepatitis C, Chronic, Middle Aged, Overweight, Body Mass Index, Cohort Studies, Fatty Liver, Alcoholism, Sex Factors, Risk Factors, Disease Progression, Prevalence, Humans, Female, Obesity, Aged, Retrospective Studies
Abstract: The aim of this study was to investigate the prevalence of hepatosteatosis in chronic hepatitis C patients, evaluate the potential impact of some host- and virus-related factors on its occurrence and possible influence of steatosis on the consequences of hepatitis.The case records of 387 patients with hepatitis C and cirrhosis were studied. The prevalence and grade of steatosis were investigated and evaluated by logistic regression analysis as dependent variable to age, gender, alcohol consumption, body mass index, hepatitis C virus (HCV) genotypes, liver enzymes activity, histological activity index and fibrosis.Steatosis was found in 47.3% of the patients. It was more prevalent in males, alcohol abusers, overweight and obese patients, and in those with HCV genotypes 3 and 2. Multivariate analysis confirmed body mass index as an independent risk factor for steatosis in the overall patient cohort and in those with genotypel without any correlation with the steatosis grade. The prevalence and grade of steatosis were associated with alcohol consumption and higher fibrosis stage. The age of the patients showed converse association.The male gender, body mass index, alcohol consumption, genotype 2 and 3 were confirmed as risk factors for hepatosteatosis. Older patients had a lesser steatosis grade. The correlation of histological activity index and fibrosis scores with the prevalence and higher grade of steatosis suggested a possibility to worsen the course of hepatitis C and to accelerate disease progression.
Published: 2007

17. Properties of the Taurocholate Uptake System in Basolateral Rat Liver Plasma Membrane Vesicles: Effects of Albumin and Substrate Specificity

Author: Zimmerli, B., primary, Valantinas, J., additional, and Meier, P. J., additional
Published: 1989
Full Text: View/download PDF

18. P1167 rs12979860 IL28B GENOTYPE IS ASSOCIATED WITH ADVANCED FIBROSIS IN HCV GENOTYPE 1-INFECTED EUROPEAN PATIENTS WITH CHRONIC HEPATITIS C: RESULTS FROM THE INTERNATIONAL GEN-C STUDY

Author: Mangia, A., primary, De Ledinghen, V., additional, Bailly, F., additional, Brahm, J., additional, Keiss, J., additional, Valantinas, J., additional, Rasmann, N., additional, Riachi, G., additional, Messinger, D., additional, Caputo, A., additional, and Foster, G.R., additional
Published: 2014
Full Text: View/download PDF

19. 491 MINIMAL NEUROPSYCHOMOTOR DISORDERS IN PATIENTS WITH CHRONIC HEPATITIS C

Author: Savlan, I., primary, Valantinas, J., additional, Audronyte, E., additional, Aksionova, D., additional, and Liakina, V., additional
Published: 2013
Full Text: View/download PDF

20. 863 CORRELATION OF IL28B POLYMORPHISM WITH DEGREE OF FIBROSIS: ANALYSIS OF TREATMENT-NAIVE AND TREATMENT-EXPERIENCED CAUCASIAN PATIENTS INFECTED WITH HCV GENOTYPE 1 IN THE GEN-C STUDY

Author: Mangia, A., primary, de L'edinghen, V., additional, Keiss, J., additional, Valantinas, J., additional, Brahm, J., additional, Rasmann, N., additional, Messinger, D., additional, and Tatsch, F., additional
Published: 2013
Full Text: View/download PDF

21. P685 Ulcerative colitis risk loci in Lithuanian-Latvian case control sample – a replication study

Author: Skieceviciene, J., primary, Kupcinskas, L., additional, Jonaitis, L., additional, Zvirbliene, A., additional, Denapiene, G., additional, Valantinas, J., additional, Leja, M., additional, Derovs, A., additional, Kiudelis, G., additional, Schreiber, S., additional, and Franke, A., additional
Published: 2013
Full Text: View/download PDF

22. P686 Thiopurine methyltransferase polymorphism in Lithuanian inflammatory bowel disease patients

Author: Kupcinskas, J., primary, Steponaitiene, R., additional, Kiudelis, G., additional, Denapiene, G., additional, Valantinas, J., additional, Jonaitis, L., additional, Kupcinskas, L., additional, and Skieceviciene, J., additional
Published: 2013
Full Text: View/download PDF

23. On the use of Le Gall wavelets in implementing locally progressive digital signal coding idea

Author: Valantinas, J., primary
Published: 2009
Full Text: View/download PDF

24. 196 PREDICTION OF CARDIAC DYSFUNCTION IN CIRRHOTIC PATIENTS USING STANDARD ECHOCARDIOGRAPHY AND COLOUR DOPPLER MYOCARDIAL IMAGING

Author: Irnius, A., primary, Grabauskiene, V., additional, Liakina, V., additional, Brasiskiene, S., additional, Jaseviciute, A., additional, and Valantinas, J., additional
Published: 2009
Full Text: View/download PDF

25. 611 DIFFERENT CHANGES OF PERIPHERAL BLOOD CD19CD5 COUNT AND TH1/TH2 CYTOKINES CONCENTRATION DURING THERAPY OF CHRONIC HEPATITIS C PATIENTS DEPENDING ON TREATMENT RESPONSE

Author: Liakina, V., primary, Speiciene, D., additional, Siaurys, A., additional, Jakutiene, J., additional, Titova, B., additional, Irnius, A., additional, and Valantinas, J., additional
Published: 2008
Full Text: View/download PDF

26. P.220 Host factors are essential for hepatic steatosis in a Lithuanian cohort of patients with chronic hepatitis C infection

Author: Speiciene, D., primary, Irnius, A., additional, Liakina, V., additional, Semuchiniene, T., additional, and Valantinas, J., additional
Published: 2006
Full Text: View/download PDF

27. A new approach to improving fractal image compression times

Author: Zumbakis, T., primary and Valantinas, J., additional
Published: 2005
Full Text: View/download PDF

28. Improving compression time in zero-tree based image coding procedures.

Author: Valantinas, J. and Kan?elkis, D.
Published: 2010
Full Text: View/download PDF

29. Accelerating compression times in block based fractal image coding procedures.

Author: Valantinas, J., Morkevicius, N., and Zumbakis, T.
Published: 2002
Full Text: View/download PDF

30. Multispecificity of Na+-dependent taurocholate uptake in basolateral (sinusoidal) rat liver plasma membrane vesicles.

Author: Zimmerli, B, Valantinas, J, and Meier, P J
Abstract: To test the hypothesis of broad specificity of the hepatocellular bile acid uptake system(s) we investigated the kinetics and substrate specificity of Na+-dependent taurocholate uptake in basolateral (sinusoidal) rat liver plasma membrane vesicles in the presence and absence of bovine serum albumin. Bovine serum albumin selectively stimulated the Na+-dependent portion of taurocholate uptake and decreased its apparent Km from 46 +/- 6 to 17 +/- 3 microM, whereas it had no effect on Vmax (4.2 +/- 0.2 nmol.mg-1.min-1). Based on complementary analysis by Dixon- and Cornish-Bowden-plots the following compounds were identified as competitive inhibitors of Na+-dependent taurocholate uptake: cholate (Ki = 140 +/- 30 microM); taurochenodeoxycholate (Ki = 9 +/- 3 microM); chenodeoxycholate (Ki = 53 +/- 6 microM); progesterone (Ki = 110 +/- 30 microM); 17-beta-estradiol-3-sulfate (Ki = 28 +/- 4 microM); bumetanide (Ki = 440 +/- 85 microns); furosemide (Ki = 460 +/- 140 microM); verapamil (Ki = 65 +/- 35 microM); and phalloidin (Ki = 850 +/- 350 microM). In contrast, noncompetitive inhibition was found with bromosulfophthalein (Ki = 12 +/- 2 microM), cyclosporin A (Ki = 3 +/- 1 microM) and 4,4'-diisothiocyano-2,2'-disulfonic acid stilbene (Ki = 45 +/- 7 microM). These results support the concept of multispecificity of the Na+-dependent basolateral bile acid uptake system with respect to different bile acids and drugs. In addition, the findings provide further evidence for bile acids and bromosulfophthalein being taken up into rat hepatocytes by different transport systems, thus supporting the assumption of multiple basolateral organic anion "carriers" with distinct, yet partially overlapping substrate specificities.
Published: 1989

31. Bicarbonate sulfate exchange in canalicular rat liver plasma membrane vesicles

Author: Meier, P. J., primary, Valantinas, J., additional, Hugentobler, G., additional, and Rahm, I., additional
Published: 1987
Full Text: View/download PDF

32. Accelerating compression times in block based fractal image coding procedures

Author: Valantinas, J., primary, Morkevicius, N., additional, and Zumbakis, T., additional
Full Text: View/download PDF

33. Problem-oriented change of image dimensionality.

Author: Valantinas, J. and Valantinas, R.
Published: 2003
Full Text: View/download PDF

34. Advancing the global public health agenda for NAFLD: a consensus statement

Author: Lazarus, Jeffrey V., Mark, Henry E., Anstee, Quentin M., Arab, Juan Pablo, Batterham, Rachel L., Castera, Laurent, Cortez-Pinto, Helena, Crespo, Javier, Cusi, Kenneth, Dirac, M. Ashworth, Francque, Sven, Hickman, Ingrid J., Hocking, Samantha L., Hunyady, Bela, Idilman, Ramazan, Isakov, Vasily A., Jamal, Mohammad H., Jepsen, Peter, Iskandar, Natacha Jreige, Song, Myeong Jun, Sudhamshu, K. C., George, Jacob, Kakizaki, Satoru, Kalamitsis, George, Kanwal, Fasiha, Kao, Jia-Horng, Kaplan, Lee, Kawaguchi, Takumi, Khader, Yousef, Kim, Seung Up, Kodjoh, Nicolas, Koek, Ger, Hagström, Hannes, Koike, Kazuhiko, Komas, Narcisse Patrice, Korenjak, Marko, Kugelmas, Marcelo, Labidi, Asma, Lange, Naomi F., Lavine, Joel E., Lazo, Mariana, Lee, Nancy, Lesmana, Cosmas Rinaldi A., Huang, Terry T.-K., Liu, Chun-Jen, Long, Michelle T., Lopez-Jaramillo, Patricio, Malekzadeh, Reza, Mahtab, Mamun Al, Marchesini, Giulio, Marinho, Rui, Vázquez, Sophia E. Martínez, Mateva, Lyudmila, Nlombi, Charles Mbendi, Ismail, Mona H., Melin, Pascal, Mikolasevic, Ivana, Milovanovic, Tamara, Musso, Carla, Nakajima, Atsushi, Nava, Edna, Nersesov, Alexander V., Nikolova, Dafina, Norris, Suzanne, Novak, Katja, Kautz, Achim, Oben, Jude, Ong, Janus P., Onyekwere, Charles, Papatheodoridis, George, Paruk, Imran, Patel, Keyur, Macedo, M. Paula, Penha-Gonçalves, Carlos, Figueroa, Marlene Pérez, Hofmann, Wolf Peter, Sarin, Shiv Kumar, Petta, Salvatore, de Oliveira, Claudia Pinto Marques Souza, Puri, Puneet, Pan, Calvin Q., Rac, Marek, Ralston, Johanna, Ramji, Alnoor, Razavi, Homie, Alvares-da-Silva, Mario Reis, Roberts, Stuart, Loomba, Rohit, Roden, Michael, Rose, Tamsin, Rouabhia, Samir, Rovere-Querini, Patrizia, Rowe, Ian A., Sadirova, Shakhlo, Salupere, Riina, Saparbu, Tobokalova, Sayegh, Raymond, Sebastiani, Giada, Miller, Veronica, Seki, Yosuke, Selmo, Josefina, Serme, Abdel Karim, Shaw, Jonathan E., Shenoy, Thrivikrama, Sheron, Nick, Shibolet, Oren, Silva, Marcelo, Skrypnyk, Igor, Socha, Piotr, Newsome, Philip N., Soriano, Joan, Spearman, C. Wendy, Sridharan, Kannan, Suárez, Juan José, Sheriff, Dhastagir Sultan, Sung, Ki-Chul, Swain, Mark, Tacke, Frank, Taheri, Shahrad, Tan, Soek-Siam, Ninburg, Michael, Tapper, Elliot B., Yki-Järvinen, Hannele, Thiele, Maja, Shawa, Isaac Thom, Tolmane, Ieva, Torres, Esther A., Trauner, Michael, Treeprasertsuk, Sombat, Turcanu, Adela, Valantinas, Jonas, Ocama, Ponsiano, Vesterhus, Mette, Waked, Imam, Wild, Sarah H., Willemse, Jose, Wong, Robert J., Xanthakos, Stavra, Young, Dan Yock, Yu, Ming-Lung, Zheng, Kenneth I., Zeybel, Mudjat, Ratziu, Vlad, Zheng, Ming-Hua, Rinella, Mary, Romero, Diana, Romero-Gómez, Manuel, Schattenberg, Jörn M., Tsochatzis, Emmanuel A., Valenti, Luca, Wong, Vincent Wai-Sun, Yilmaz, Yusuf, Younossi, Zobair M., Zelber-Sagi, Shira, Åberg, Fredrik, Adams, Leon, Khatry, Maryam Salem Al, Naamani, Khalid Al, Murillo, Omar Alfaro, Allen, Alina M., Alnaser, Faisal, Alqahtani, Saleh A., Alswat, Khalid, Alvaro, Domenico, Andrade, Raúl J., Arrese, Marco, Awuku, Yaw Asante, Ayesha, Motala, Baatarkhuu, Oidov, Bakieva, Shokhista, Basu, Rita, Bataller, Ramon, Bedri, Shahinaz, Bosi, Emanuele, Bourliere, Marc, Bruha, Radan, Bugianesi, Elisabetta, Burra, Patrizia, Buti, Maria, Byrne, Christopher D., Calleja, Jose Luis, Carrieri, Patrizia, Carter, Flloyd, Fernandez, Marlen Ivon Castellanos, Castillo-Lopez, Gabriela, Castro-Narro, Graciela E., Chan, Henry Lik Yuen, Chan, Wah-Kheong, Chang, Yoosoo, Colombo, Massimo, Coppell, Kirsten J., Corey, Kathleen, Craxi, Antonio, Cryer, Donna, Dassanayake, Anuradha, Martins, Antonieta de Ascenção Soares, de Ledinghen, Victor, DelPrato, Stefano, Demaio, Alessandro, Desalegn, Hailemichael, Dillon, John, Duseja, Ajay, Dorairaj, Prabhakaran, Ekstedt, Mattias, El Kassas, Mohamed, Elsanousi, Osama M., Esmat, Gamal, Fan, Jian-Gao, Farpour-Lambert, Nathalie, Flisiak, Robert, Fouad, Yasser, Fuchs, Michael, Gani, Rino A., Gerber, Lynn, Ghazinyan, Hasmik, Gheorghe, Liana, Goh, George Boon-Bee, Grønbæk, Henning, Gulnara, Aghayeva, Hamid, Saeed, Hebditch, Vanessa, Repositório da Universidade de Lisboa, Masira, Lazarus, Jeffrey, V, Mark, Henry E., Anstee, Quentin M., Arab, Juan Pablo, Batterham, Rachel L., Castera, Laurent, Cortez-Pinto, Helena, Crespo, Javier, Cusi, Kenneth, Dirac, M. Ashworth, Francque, Sven, George, Jacob, Hagstrom, Hannes, Huang, Terry T-K, Ismail, Mona H., Kautz, Achim, Sarin, Shiv Kumar, Loomba, Rohit, Miller, Veronica, Newsome, Philip N., Ninburg, Michael, Ocama, Ponsiano, Ratziu, Vlad, Rinella, Mary, Romero, Diana, Romero-Gomez, Manuel, Schattenberg, Jorn M., Tsochatzis, Emmanuel A., Valenti, Luca, Wong, Vincent Wai-Sun, Yilmaz, Yusuf, Younossi, Zobair M., Zelber-Sagi, Shira, Lazarus, J. V., Mark, H. E., Anstee, Q. M., Arab, J. P., Batterham, R. L., Castera, L., Cortez-Pinto, H., Crespo, J., Cusi, K., Dirac, M. A., Francque, S., George, J., Hagstrom, H., Huang, T. T. -K., Ismail, M. H., Kautz, A., Sarin, S. K., Loomba, R., Miller, V., Newsome, P. N., Ninburg, M., Ocama, P., Ratziu, V., Rinella, M., Romero, D., Romero-Gomez, M., Schattenberg, J. M., Tsochatzis, E. A., Valenti, L., Wong, V. W. -S., Yilmaz, Y., Younossi, Z. M., Zelber-Sagi, S., Aberg, F., Adams, L., Khatry, M. S. A., Naamani, K. A., Murillo, O. A., Allen, A. M., Alnaser, F., Alqahtani, S. A., Alswat, K., Alvaro, D., Andrade, R. J., Arrese, M., Awuku, Y. A., Ayesha, M., Baatarkhuu, O., Bakieva, S., Basu, R., Bataller, R., Bedri, S., Bosi, E., Bourliere, M., Bruha, R., Bugianesi, E., Burra, P., Buti, M., Byrne, C. D., Calleja, J. L., Carrieri, P., Carter, F., Fernandez, M. I. C., Castillo-Lopez, G., Castro-Narro, G. E., Chan, H. L. Y., Chan, W. -K., Chang, Y., Colombo, M., Coppell, K. J., Corey, K., Craxi, A., Cryer, D., Dassanayake, A., Martins, A. A. S., de Ledinghen, V., Delprato, S., Demaio, A., Desalegn, H., Dillon, J., Duseja, A., Dorairaj, P., Ekstedt, M., El Kassas, M., Elsanousi, O. M., Esmat, G., Fan, J. -G., Farpour-Lambert, N., Flisiak, R., Fouad, Y., Fuchs, M., Gani, R. A., Gerber, L., Ghazinyan, H., Gheorghe, L., Goh, G. B. -B., Gronbaek, H., Gulnara, A., Hamid, S., Hebditch, V., Hickman, I. J., Hocking, S. L., Hunyady, B., Idilman, R., Isakov, V. A., Jamal, M. H., Jepsen, P., Iskandar, N. J., Song, M. J., Sudhamshu, K. C., Kakizaki, S., Kalamitsis, G., Kanwal, F., Kao, J. -H., Kaplan, L., Kawaguchi, T., Khader, Y., Kim, S. U., Kodjoh, N., Koek, G., Koike, K., Komas, N. P., Korenjak, M., Kugelmas, M., Labidi, A., Lange, N. F., Lavine, J. E., Lazo, M., Lee, N., Lesmana, C. R. A., Liu, C. -J., Long, M. T., Lopez-Jaramillo, P., Malekzadeh, R., Mahtab, M. A., Marchesini, G., Marinho, R., Vazquez, S. E. M., Mateva, L., Nlombi, C. M., Melin, P., Mikolasevic, I., Milovanovic, T., Musso, C., Nakajima, A., Nava, E., Nersesov, A. V., Nikolova, D., Norris, S., Novak, K., Oben, J., Ong, J. P., Onyekwere, C., Papatheodoridis, G., Paruk, I., Patel, K., Macedo, M. P., Penha-Goncalves, C., Figueroa, M. P., Hofmann, W. P., Petta, S., de Oliveira, C. P. M. S., Puri, P., Pan, C. Q., Rac, M., Ralston, J., Ramji, A., Razavi, H., Alvares-da-Silva, M. R., Roberts, S., Roden, M., Rose, T., Rouabhia, S., Rovere-Querini, P., Rowe, I. A., Sadirova, S., Salupere, R., Saparbu, T., Sayegh, R., Sebastiani, G., Seki, Y., Selmo, J., Serme, A. K., Shaw, J. E., Shenoy, T., Sheron, N., Shibolet, O., Silva, M., Skrypnyk, I., Socha, P., Soriano, J., Spearman, C. W., Sridharan, K., Suarez, J. J., Sheriff, D. S., Sung, K. -C., Swain, M., Tacke, F., Taheri, S., Tan, S. -S., Tapper, E. B., Yki-Jarvinen, H., Thiele, M., Shawa, I. T., Tolmane, I., Torres, E. A., Trauner, M., Treeprasertsuk, S., Turcanu, A., Valantinas, J., Vesterhus, M., Waked, I., Wild, S. H., Willemse, J., Wong, R. J., Xanthakos, S., Young, D. Y., Yu, M. -L., Zheng, K. I., Zeybel, M., Zheng, M. -H., NAFLD Consensus Consortium, Lazarus J.V., Mark H.E., Anstee Q.M., Arab J.P., Batterham R.L., Castera L., Cortez-Pinto H., Crespo J., Cusi K., Dirac M.A., Francque S., George J., Hagstrom H., Huang T.T.-K., Ismail M.H., Kautz A., Sarin S.K., Loomba R., Miller V., Newsome P.N., Ninburg M., Ocama P., Ratziu V., Rinella M., Romero D., Romero-Gomez M., Schattenberg J.M., Tsochatzis E.A., Valenti L., Wong V.W.-S., Yilmaz Y., Younossi Z.M., Zelber-Sagi S., Aberg F., Adams L., Khatry M.S.A., Naamani K.A., Murillo O.A., Allen A.M., Alnaser F., Alqahtani S.A., Alswat K., Alvaro D., Andrade R.J., Arrese M., Awuku Y.A., Ayesha M., Baatarkhuu O., Bakieva S., Basu R., Bataller R., Bedri S., Bosi E., Bourliere M., Bruha R., Bugianesi E., Burra P., Buti M., Byrne C.D., Calleja J.L., Carrieri P., Carter F., Fernandez M.I.C., Castillo-Lopez G., Castro-Narro G.E., Chan H.L.Y., Chan W.-K., Chang Y., Colombo M., Coppell K.J., Corey K., Craxi A., Cryer D., Dassanayake A., Martins A.A.S., de Ledinghen V., DelPrato S., Demaio A., Desalegn H., Dillon J., Duseja A., Dorairaj P., Ekstedt M., El Kassas M., Elsanousi O.M., Esmat G., Fan J.-G., Farpour-Lambert N., Flisiak R., Fouad Y., Fuchs M., Gani R.A., Gerber L., Ghazinyan H., Gheorghe L., Goh G.B.-B., Gronbaek H., Gulnara A., Hamid S., Hebditch V., Hickman I.J., Hocking S.L., Hunyady B., Idilman R., Isakov V.A., Jamal M.H., Jepsen P., Iskandar N.J., Song M.J., Sudhamshu K.C., Kakizaki S., Kalamitsis G., Kanwal F., Kao J.-H., Kaplan L., Kawaguchi T., Khader Y., Kim S.U., Kodjoh N., Koek G., Koike K., Komas N.P., Korenjak M., Kugelmas M., Labidi A., Lange N.F., Lavine J.E., Lazo M., Lee N., Lesmana C.R.A., Liu C.-J., Long M.T., Lopez-Jaramillo P., Malekzadeh R., Mahtab M.A., Marchesini G., Marinho R., Vazquez S.E.M., Mateva L., Nlombi C.M., Melin P., Mikolasevic I., Milovanovic T., Musso C., Nakajima A., Nava E., Nersesov A.V., Nikolova D., Norris S., Novak K., Oben J., Ong J.P., Onyekwere C., Papatheodoridis G., Paruk I., Patel K., Macedo M.P., Penha-Goncalves C., Figueroa M.P., Hofmann W.P., Petta S., de Oliveira C.P.M.S., Puri P., Pan C.Q., Rac M., Ralston J., Ramji A., Razavi H., Alvares-da-Silva M.R., Roberts S., Roden M., Rose T., Rouabhia S., Rovere-Querini P., Rowe I.A., Sadirova S., Salupere R., Saparbu T., Sayegh R., Sebastiani G., Seki Y., Selmo J., Serme A.K., Shaw J.E., Shenoy T., Sheron N., Shibolet O., Silva M., Skrypnyk I., Socha P., Soriano J., Spearman C.W., Sridharan K., Suarez J.J., Sheriff D.S., Sung K.-C., Swain M., Tacke F., Taheri S., Tan S.-S., Tapper E.B., Yki-Jarvinen H., Thiele M., Shawa I.T., Tolmane I., Torres E.A., Trauner M., Treeprasertsuk S., Turcanu A., Valantinas J., Vesterhus M., Waked I., Wild S.H., Willemse J., Wong R.J., Xanthakos S., Young D.Y., Yu M.-L., Zheng K.I., Zeybel M., and Zheng M.-H.
Subjects: medicine.medical_specialty, Civil society, Delphi method, MEDLINE, Nash, MULTIDISCIPLINARY APPROACH, Disease, LATIN-AMERICAN ASSOCIATION, Multidisciplinary approach, QUALITY-OF-LIFE, Non-alcoholic Fatty Liver Disease, Epidemiology, Medicine, Humans, POSITION STATEMENT, BIOMEDICINE AND HEALTHCARE. Clinical Medical Sciences. Internal Medicine, FATTY LIVER-DISEASE, BIOMEDICINA I ZDRAVSTVO. Kliničke medicinske znanosti. Interna medicina, Hepatology, business.industry, Public health, Gastroenterology, ALCOHOLIC STEATOHEPATITIS, NONINVASIVE DIAGNOSIS, medicine.disease, Obesity, CARDIOVASCULAR-DISEASE, PRACTICE GUIDELINES, Family medicine, PRACTICAL APPROACH, Human medicine, business
Abstract: Digital, Non-alcoholic fatty liver disease (NAFLD) is a potentially serious liver disease that affects approximately one-quarter of the global adult population, causing a substantial burden of ill health with wide-ranging social and economic implications. It is a multisystem disease and is considered the hepatic component of metabolic syndrome. Unlike other highly prevalent conditions, NAFLD has received little attention from the global public health community. Health system and public health responses to NAFLD have been weak and fragmented, and, despite its pervasiveness, NAFLD is largely unknown outside hepatology and gastroenterology. There is only a nascent global public health movement addressing NAFLD, and the disease is absent from nearly all national and international strategies and policies for non-communicable diseases, including obesity. In this global Delphi study, a multidisciplinary group of experts developed consensus statements and recommendations, which a larger group of collaborators reviewed over three rounds until consensus was achieved. The resulting consensus statements and recommendations address a broad range of topics — from epidemiology, awareness, care and treatment to public health policies and leadership — that have general relevance for policy-makers, health-care practitioners, civil society groups, research institutions and affected populations. These recommendations should provide a strong foundation for a comprehensive public health response to NAFLD., Ciencias Médicas y de la Salud
Published: 2021

35. The case for simplifying and using absolute targets for viral hepatitis elimination goals

Author: Tsendsuren S. Oyunsuren, Chari Cohen, Waseem Hamoudi, Yao‐Chun Hsu, Harry L.A. Janssen, Hisham El Khayat, Manal H El-Sayed, Wan-Long Chuang, Young-Suk Lim, Mohamed Hassany, Fernando Passos Cupertino de Barros, Faisal Abaalkhail, Stefan Zeuzem, Samual S Lee, Miriam T. Levy, Imam Waked, Vassiliki Papaevangelou, James Fung, Erika Castro Batänjer, Kathryn Razavi-Shearer, Boatemaa Ntiri‐ Reid, Rosmawati Mohamed, Pagbajabyn Nymadawa, Robert Flisiak, Alnoor Ramji, Carole Seguin-Devaux, Sherif Mogawer, Béla Hunyady, Huma Qureshi, Mojca Matičič, Martin Lagging, Mark W. Sonderup, Xiaoguang Dou, Anne Oevrehus, William Sievert, Ezequiel Ridruejo, Ann-Sofi Duberg, Ahad Eshraghian, R. P. Shanmugam, Arif Nawaz, Qing Xie, Rick Dunn, Sayed Himatt, Daniel Shouval, Mendez Sanchez Nahum, Sabahattin Kaymakoglu, Vincent Wai-Sun Wong, Soek-Siam Tan, Willis Maddrey, Papu Prasad, Amjad Salamat, Stephanie Popping, Alice Lee, Maurizia Rossana Brunetto, Khalid Alswat, Peyton Thompson, Dong Joon Kim, Henry Chang, Amir Ali Sohrabpour, Ellen Dugan, Peer Brehm Christensen, David A. M. C. van de Vijver, Joaquín Cabezas, Su Wang, Ala I. Sharara, Peter Jarcuska, Karine Lacombe, Danjuma Adda, Sammy Saab, Chien-Jen Chen, Hwai I. Yang, Sanaa Said, Raymond F. Schinazi, Shyamasundaran Kottilil, Graham R. Foster, Qing Ning, Mehlika Toy, Ira M. Jacobson, Ayat R. Abdallah, Laura Cisneros, Dhondup Tashi, Naveed Z. Janjua, Moutaz Derbala, Marcelo Kugelmas, Steven L. Flamm, Angelos Hatzakis, Yusuf Yilmaz, Mark S. Sulkowski, Eugene R. Schiff, Kakharman Yesmembetov, John F. Dillon, Rittoo Prithiviputh, Carlos Eduardo Brandão-Mello, Rajender Reddy, Françoise Roudot-Thoraval, Lewis R. Roberts, Javier Crespo, Massimo Colombo, Nancy Steinfurth, I. M. Hoepelman, Kosh Agarwal, Faisal M. Sanai, Waleed Al-Hamoudi, Shuang Liu, Beat Muellhaupt, Sonjelle Shilton, Curtis Cooper, Calvin Q. Pan, Aijaz Ahmed, Wai-cheung C Lao, Alejandro Soza, Patricia Vélez‐Möller, Ibrahim Altraif, Tarik Asselah, Junko Tanaka, Badr Aljarallah, Adriana Vince, Faryal Khamis, Juan Francisco Sánchez-Ávila, Rafael Esteban Mur, Kimberly A. Brown, Saad Al-Kaabi, Ming-Lung Yu, Jonas Valantinas, Marieta Simonova, Javier García-Samaniego, Do Young Kim, Ieva Tolmane, Valentina Liakina, Antonio Craxì, Devin Razavi-Shearer, Waldemar Halota, Stuart K. Roberts, Donna Cryer, Kenneth Kabagambe, William Remak, Jeffrey V. Lazarus, Brian Conway, Sameera Ezzat, C Wendy Spearman, Karolin Falconer, Maria C Mendes Correa, Poonam Mathur, Ferruccio Bonino, Jose Luis Calleja, Said A. Al-Busafi, E. A. Croes, Tim Block, Shahin Merat, Francesco Negro, Reza Malekzadeh, Fernando L. Gonçales, Amany Zekry, Wahid Doss, Michael Ninburg, Philip Bruggmann, Man-Fung Yuen, George V. Papatheodoridis, Aasim Yusuf, David Kershenobich, Bruce R. Bacon, Abdul Rahman Bizri, Gamal Esmat, Sarah Blach, Hamad Al-Romaihi, Tatsuya Kanto, Ibrahim Mostafa, Homie Razavi, Alessio Aghemo, Mauricio Orrego, Jia-Horng Kao, Daniel Lavanchy, Zobair M. Younossi, Henry Lik-Yuen Chan, Anna Kramvis, David H. Muljono, Clemens Richter, Hla-Hla Thein, Fernando Bessone, Paulo Roberto Abrão Ferreira, Geoffrey Dusheiko, Susan Hay, Geert Robaeys, Eduardo Fassio, Loreta A. Kondili, Jorge Mera, Khalid Al-Naamani, Alaa Osman, Saleh A. Alqahtani, Joseph Doyle, Necati Örmeci, Yee Tak Hui, Heiner Wedemeyer, Laith Jamal Abu Raddad, Masayuki Kurosaki, Rui Tato Marinho, Robert G. Gish, Zaigham Abbas, Seiji Yamada, Giada Sebastiani, Cihan Yurdaydin, Maria Buti, Paulo Ferrinho, Razavi H., Blach S., Razavi-Shearer D., Abaalkhail F., Abbas Z., Abdallah A., Abrao Ferreira P., Abu Raddad L.J., Adda D., Agarwal K., Aghemo A., Ahmed A., Al-Busafi S.A., Al-hamoudi W., Al-Kaabi S., Al-Romaihi H., Aljarallah B., AlNaamani K., Alqahtani S., Alswat K., Altraif I., Asselah T., Bacon B., Bessone F., Bizri A.R., Block T., Bonino F., Brandao-Mello C.E., Brown K., Bruggmann P., Brunetto M.R., Buti M., Cabezas J., Calleja J.L., Castro Batanjer E., Chan H.L.-Y., Chang H., Chen C.-J., Christensen P.B., Chuang W.-L., Cisneros L., Cohen C., Colombo M., Conway B., Cooper C., Craxi A., Crespo J., Croes E., Cryer D., Cupertino de Barros F.P., Derbala M., Dillon J., Doss W., Dou X., Doyle J., Duberg A.-S., Dugan E., Dunn R., Dusheiko G., El Khayat H., El-Sayed M.H., Eshraghian A., Esmat G., Esteban Mur R., Ezzat S., Falconer K., Fassio E., Ferrinho P., Flamm S., Flisiak R., Foster G., Fung J., Garcia-Samaniego J., Gish R.G., Goncales F., Halota W., Hamoudi W., Hassany M., Hatzakis A., Hay S., Himatt S., Hoepelman I.M., Hsu Y.-C., Hui Y.T., Hunyady B., Jacobson I., Janjua N., Janssen H., Jarcuska P., Kabagambe K., Kanto T., Kao J.-H., Kaymakoglu S., Kershenobich D., Khamis F., Kim D.J., Kim D.Y., Kondili L.A., Kottilil S., Kramvis A., Kugelmas M., Kurosaki M., Lacombe K., Lagging M., Lao W.-C., Lavanchy D., Lazarus J.V., Lee A., Lee S.S., Levy M., Liakina V., Lim Y.-S., Liu S., Maddrey W., Malekzadeh R., Marinho R.T., Mathur P., Maticic M., Mendes Correa M.C., Mera J., Merat S., Mogawer S., Mohamed R., Muellhaupt B., Muljono D., Mostafa I., Nahum M.S., Nawaz A., Negro F., Ninburg M., Ning Q., Ntiri- Reid B., Nymadawa P., Oevrehus A., Ormeci N., Orrego M., Osman A., Oyunsuren T., Pan C., Papaevangelou V., Papatheodoridis G., Popping S., Prasad P., Prithiviputh R., Qureshi H., Ramji A., Razavi-Shearer K., Reddy R., Remak W., Richter C., Ridruejo E., Robaeys G., Roberts S., Roberts L., Roudot-Thoraval F., Saab S., Said S., Salamat A., Sanai F., Sanchez-Avila J.F., Schiff E., Schinazi R., Sebastiani G., Seguin-Devaux C., Shanmugam R.P., Sharara A., Shilton S., Shouval D., Sievert W., Simonova M., Sohrabpour A.A., Sonderup M., Soza A., Wendy Spearman C., Steinfurth N., Sulkowski M., Tan S.-S., Tanaka J., Tashi D., Thein H.-H., Thompson P., Tolmane I., Toy M., Valantinas J., Van de Vijver D., Velez-Moller P., Vince A., Waked I., Wang S., Wedemeyer H., Wong V., Xie Q., Yamada S., Yang H.-I., Yesmembetov K., Yilmaz Y., Younossi Z., Yu M.-L., Yuen M.-F., Yurdaydin C., Yusuf A., Zekry A., Zeuzem S., Medical Microbiology & Infectious Diseases, Virology, and Negro, Francesco
Subjects: ddc:616, Carcinoma, Hepatocellular, Hepatology, Hepatitis, Viral, Human, business.industry, Liver Neoplasms, ddc:616.07, medicine.disease, World Health Organization, Virology, digestive system diseases, Goal, Infectious Diseases, Absolute (philosophy), SDG 3 - Good Health and Well-being, medicine, Humans, Viral hepatitis, business, Goals, Human
Abstract: The 69th World Health Assembly endorsed the Global Health Sector Strategy for Viral Hepatitis, embracing a goal to eliminate hepatitis infection as a public health threat by 2030. This was followed by the World Health Organization's (WHO) global targets for the care and management of hepatitis B virus (HBV) and hepatitis C virus (HCV) infections. These announcements and targets were important in raising awareness and calling for action; however, tracking countries’ progress towards these elimination goals has provided insights to the limitations of these targets. The existing targets compare a country's progress relative to its 2015 values, penalizing countries who started their programmes prior to 2015, countries with a young population, or countries with a low prevalence. We recommend that (1) WHO simplify the hepatitis elimination targets, (2) change to absolute targets and (3) allow countries to achieve these disease targets with their own service coverage initiatives that will have the maximum impact. The recommended targets are as follows: reduce HCV new chronic cases to ≤5 per 100000, reduce HBV prevalence among 1-year-olds to ≤0.1%, reduce HBV and HCV mortality to ≤5 per 100000, and demonstrate HBV and HCV year-to-year decrease in new HCV- and HBV-related HCC cases. The objective of our recommendations is not to lower expectations or diminish the hepatitis elimination standards, but to provide clearer targets that recognize the past and current elimination efforts by countries, help measure progress towards true elimination, and motivate other countries to follow suit.
Published: 2021

36. Global prevalence and genotype distribution of hepatitis C virus infection in 2015:a modelling study

Author: Hans Van Vlierberghe, Soo Aleman, Naveed Z. Janjua, Henry Lik-Yuen Chan, Olufunmilayo A. Lesi, Irena Hrstić, Abdullah M. Assiri, William Rosenberg, Moon sing Lai, Vladimir Chulanov, Jan Sperl, Beat Müllhaupt, Michael Manns, William Sievert, Sabahattin Kaymakoglu, Cesar Yaghi, Evy Yunihastuti, Pierre Van Damme, Jon G. Jonasson, Antonio Javier Blasco, Young Sik Kim, S. Olafsson, Rohani Jahis, Christoph Sarrazin, Manik Sharma, Aasim Yusuf, Omer Hajelssedig, Javier García-Samaniego, Boris Lukšić, Peter Stärkel, Stefan Zeuzem, Stephen Oguche, E. A. Croes, Abdullah S. Alghamdi, Richard Njouom, CE Omuemu, Carlos E Brandão Mello, Adam Mahomed, Behzad Hajarizadeh, Ogu Omede, Said A. Al-Busafi, Sarah Robbins, Peer Brehm Christensen, Ammal M. Metwally, Béla Hunyady, Gamal Esmat, Ivane Gamkrelidze, Maheeba Abdulla, Suzanne Norris, Sarah Blach, Harald Hofer, Maria C Mendes Correa, Devin Razavi-Shearer, Matti Maimets, Chien-Jen Chen, Peter Jarcuska, Marian Oltman, Francesco Negro, Ilias Gountas, Ayman Yosry, Sona Frankova, Adrian Goldis, Laurentius A. Lesmana, Ivan Schréter, Danute Speiciene, Kevork M. Peltekian, Berhane Redae, Stuart K. Roberts, Valentina Liakina, Seyed M Alavian, Wai-cheung C Lao, Ziv Ben-Ari, Imad Al Ghazzawi, Cheryl Brunton, Rudolf E. Stauber, Akram Khan, Tung-Hung Su, Manal H El-Sayed, Kimberly Murphy, Kyriakos Souliotis, Adriana Vince, Ramazan Idilman, Christophe Moreno, Angelos Hatzakis, Lewis R. Roberts, Richard Phillips, Jason Grebely, Michael Gschwantler, Hugo Cheinquer, Vana Sypsa, Samir Shah, Wolfgang Vogel, M. Blachier, Abate Bane, Henri Leleu, Saeed Hamid, Ohene Opare-Sem, Hamad Al-Romaihi, Wan-Long Chuang, Alexander J. Thompson, Agita Jeruma, Robert Flisiak, Catherine A.M. Stedman, Ingo van Thiel, Carole Seguin-Devaux, Jonathan Schmelzer, Juan F.Sanchez Avila, Rui Tato Marinho, Muhammad S. Memon, Nina Weis, Rosmawati Mohamed, Florian Bihl, Moon Seok Choi, David Kershenobich, Vic Arendt, Yee Tak Hui, Mei Hsuan Lee, N. N. Pimenov, Saad Al Kaabi, Ken Pasini, Henrik Krarup, Stefan Mauss, Shahin Merat, Khalid Al Namaani, Rong-Nan Chien, Perttu Arkkila, Henk W. Reesink, Françoise Roudot-Thoraval, Paul Marotta, Shirley Owusu-Ofori, Fadi H. Mourad, Abdul Rahman Bizri, Chris Estes, Heiner Wedemeyer, Faisal M. Sanai, Mihály Makara, Stephen D. Ryder, Mel Krajden, Laura Cisneros, Adriaan J. van der Meer, Eli Zuckerman, Matthew E. Cramp, Rui Sarmento-Castro, Magnus Gottfredsson, Gregory J. Dore, Huma Qureshi, Yasser Kamel, Olga Sagalova, Rifaat Safadi, Wim Laleman, Solomon Obekpa, Karolin Falconer, Edward Gane, Philip Bruggmann, Fernando Bessone, Jia-Horng Kao, Daniel Lavanchy, Riina Salupere, Anne Øvrehus, Ulus Salih Akarca, Monique Andersson, Man-Fung Yuen, Ala I. Sharara, Olav Dalgard, Homie Razavi, Gamal Shiha, Paulo R. Ferreira, George V. Papatheodoridis, Anatoly Shevaldin, Jawad Khamis, Waseem Hamoudi, Kathryn Razavi-Shearer, Vincent Ws Wong, Loreta A. Kondili, Maria Lucia Gomes Ferraz, Wasim Jafri, Pablo Lázaro, Faisal Abaalkhail, David H. Muljono, Youssif Al Serkal, Imam Waked, Zaher Koutoubi, Oidov Baatarkhuu, Nahum Méndez-Sánchez, Abraham O. Malu, Daniel Struck, Helen Nde, Alnoor Ramji, Ahmed Abdou, Antoine Abou Rached, Michael Li, Diana Nonković, Jorge Daruich, Ezequiel Ridruejo, Gül Ergör, Ann-Sofi Duberg, Krzysztof Tomasiewicz, Filipe Calinas, Hossein Poustchi, Layla Al-Dabal, Jessie Gunter, Mark W. Sonderup, Colm Bergin, Mario G. Pessoa, Jonas Valantinas, Asad Chaudhry, Junko Tanaka, Tsendsuren S. Oyunsuren, Soek Siam Tan, Vivek A. Saraswat, Young-Suk Lim, Ibrahim Altraif, Victor de Ledinghen, Faryal Al Lawati, Mette Rye Clausen, Ieva Tolmane, Antonio Craxì, Abdulrahman Aljumah, Elmoubashar Farag, Inka Aho, Sayed Himatt, Nishi Prabdial-Sing, Blach S., Zeuzem S., Manns M., Altraif I., Duberg A.-S., Muljono D.H., Waked I., Alavian S.M., Lee M.-H., Negro F., Abaalkhail F., Abdou A., Abdulla M., Abou Rached A., Aho I., Akarca U., Al Ghazzawi I., Al Kaabi S., Al Lawati F., Al Namaani K., Al Serkal Y., Al-Busafi S.A., Al-Dabal L., Aleman S., Alghamdi A.S., Aljumah A.A., Al-Romaihi H.E., Andersson M.I., Arendt V., Arkkila P., Assiri A.M., Baatarkhuu O., Bane A., Ben-Ari Z., Bergin C., Bessone F., Bihl F., Bizri A.R., Blachier M., Blasco A.J., Brandao Mello C.E., Bruggmann P., Brunton C.R., Calinas F., Chan H.L.Y., Chaudhry A., Cheinquer H., Chen C.-J., Chien R.-N., Choi M.S., Christensen P.B., Chuang W.-L., Chulanov V., Cisneros L., Clausen M.R., Cramp M.E., Craxi A., Croes E.A., Dalgard O., Daruich J.R., De Ledinghen V., Dore G.J., El-Sayed M.H., Ergor G., Esmat G., Estes C., Falconer K., Farag E., Ferraz M.L.G., Ferreira P.R., Flisiak R., Frankova S., Gamkrelidze I., Gane E., Garcia-Samaniego J., Khan A.G., Gountas I., Goldis A., Gottfredsson M., Grebely J., Gschwantler M., Guimaraes Pessoa M., Gunter J., Hajarizadeh B., Hajelssedig O., Hamid S., Hamoudi W., Hatzakis A., Himatt S.M., Hofer H., Hrstic I., Hui Y.-T., Hunyady B., Idilman R., Jafri W., Jahis R., Janjua N.Z., Jarcuska P., Jeruma A., Jonasson J.G., Kamel Y., Kao J.-H., Kaymakoglu S., Kershenobich D., Khamis J., Kim Y.S., Kondili L., Koutoubi Z., Krajden M., Krarup H., Lai M.-S., Laleman W., Lao W.-C., Lavanchy D., Lazaro P., Leleu H., Lesi O., Lesmana L.A., Li M., Liakina V., Lim Y.-S., Luksic B., Mahomed A., Maimets M., Makara M., Malu A.O., Marinho R.T., Marotta P., Mauss S., Memon M.S., Mendes Correa M.C., Mendez-Sanchez N., Merat S., Metwally A.M., Mohamed R., Moreno C., Mourad F.H., Mullhaupt B., Murphy K., Nde H., Njouom R., Nonkovic D., Norris S., Obekpa S., Oguche S., Olafsson S., Oltman M., Omede O., Omuemu C., Opare-Sem O., Ovrehus A.L.H., Owusu-Ofori S., Oyunsuren T.S., Papatheodoridis G., Pasini K., Peltekian K.M., Phillips R.O., Pimenov N., Poustchi H., Prabdial-Sing N., Qureshi H., Ramji A., Razavi-Shearer D., Razavi-Shearer K., Redae B., Reesink H.W., Ridruejo E., Robbins S., Roberts L.R., Roberts S.K., Rosenberg W.M., Roudot-Thoraval F., Ryder S.D., Safadi R., Sagalova O., Salupere R., Sanai F.M., Sanchez Avila J.F., Saraswat V., Sarmento-Castro R., Sarrazin C., Schmelzer J.D., Schreter I., Seguin-Devaux C., Shah S.R., Sharara A.I., Sharma M., Shevaldin A., Shiha G.E., Sievert W., Sonderup M., Souliotis K., Speiciene D., Sperl J., Starkel P., Stauber R.E., Stedman C., Struck D., Su T.-H., Sypsa V., Tan S.-S., Tanaka J., Thompson A.J., Tolmane I., Tomasiewicz K., Valantinas J., Van Damme P., Van Der Meer A.J., Van Thiel I., Van Vlierberghe H., Vince A., Vogel W., Wedemeyer H., Weis N., Wong V.W.S., Yaghi C., Yosry A., Yuen M.-F., Yunihastuti E., Yusuf A., Zuckerman E., Razavi H., Polaris Observ HCV Collaborators, Negro, Francesco, and Ege Üniversitesi
Subjects: Viremia/epidemiology, Population ageing, medicine.medical_specialty, CIENCIAS MÉDICAS Y DE LA SALUD, Delphi Technique, Genotype, Voxilaprevir, Genotype, Global Health, Hepatitis C, Eradication, Modelling study, Medicina Clínica, ddc:616.07, Global Health, Bioinformatics, 03 medical and health sciences, 0302 clinical medicine, Cost of Illness, Epidemiology, Journal Article, medicine, Global health, Prevalence, Humans, Viremia, 030212 general & internal medicine, Disease Eradication, Disease burden, ddc:616, Hepatology, Hepatitis C, Chronic/epidemiology, business.industry, Gastroenterology, Hepatitis C, Glecaprevir, Hepatitis C, Chronic, medicine.disease, Viremia/epidemiology/genetics, Pibrentasvir, Global Health/statistics & numerical data, HCV, HEPATITIS C, 030211 gastroenterology & hepatology, Medicina Critica y de Emergencia, Human medicine, business, Chronic/epidemiology/genetics/prevention & control, Demography
Abstract: WOS: 000426979400014, PubMed ID: 28404132, Background The 69th World Health Assembly approved the Global Health Sector Strategy to eliminate hepatitis C virus (HCV) infection by 2030, which can become a reality with the recent launch of direct acting antiviral therapies. Reliable disease burden estimates are required for national strategies. This analysis estimates the global prevalence of viraemic HCV at the end of 2015, an update of-and expansion on-the 2014 analysis, which reported 80 million (95% CI 64-103) viraemic infections in 2013. Methods We developed country-level disease burden models following a systematic review of HCV prevalence (number of studies, n=6754) and genotype (n=11 342) studies published after 2013. A Delphi process was used to gain country expert consensus and validate inputs. Published estimates alone were used for countries where expert panel meetings could not be scheduled. Global prevalence was estimated using regional averages for countries without data. Findings Models were built for 100 countries, 59 of which were approved by country experts, with the remaining 41 estimated using published data alone. The remaining countries had insufficient data to create a model. The global prevalence of viraemic HCV is estimated to be 1.0% (95% uncertainty interval 0.8-1.1) in 2015, corresponding to 71.1 million (62.5-79.4) viraemic infections. Genotypes 1 and 3 were the most common cause of infections (44% and 25%, respectively). Interpretation The global estimate of viraemic infections is lower than previous estimates, largely due to more recent (lower) prevalence estimates in Africa. Additionally, increased mortality due to liver-related causes and an ageing population may have contributed to a reduction in infections., John C Martin Foundation, John C Martin Foundation.
Published: 2017

37. Teoriniai ir praktiniai fraktalinių interpoliacinių funkcijų sudarymo aspektai

Author: Jančiukaitė, Giedrė and Valantinas, J.
Subjects: fraktalinės interpoliacinės funkcijos, ComputingMethodologies_IMAGEPROCESSINGANDCOMPUTERVISION, MathematicsofComputing_NUMERICALANALYSIS, fractal interpolation function, ComputingMethodologies_COMPUTERGRAPHICS
Abstract: This thesis introduces fractal interpolation functions, exposes advantages of fractal interpolation of real world objects and presents some newly developed procedures, associated with fractal interpolation process. The work briefly presents the context needed for introduction of fractal approach and relevant definitions. Also, the detailed description of fractal generating algorithms (deterministic, random iteration, “escape time”) as well as fractal classifications is presented. Since the research object is theoretical and practical aspects of fractal interpolation function analysis, special attention is paid to geometric fractals, obtained using systems of iterated functions (IFS). The notion of a fractal interpolation function is introduced in the work. The author shows that it is possible to generate fractal interpolation functions for various types of data. The generated functions are “close” (in the sense of Housdorf dimension) to the data under processing, i.e., it is possible to ensure that the fractal interpolation graph dimension were equal to the fractal dimension of experimental data (graph). The random iteration algorithm is used for the analysis of fractal interpolation functions, since it is relatively simple and fast enough. The author makes an attempt to analyze and solve the problem of choosing interpolation points (general case). A few approaches are proposed, namely the uniform distribution of interpolation points (for the interactive use) and collage. On the other hand, the most valuable developments – procedures for the determination of „skew ness“ parameters for the affine transformations, entering the IFS. The experiment was applied to the real company‘s trade object. The experimental analysis results showed that the INTERPO software program is the tool which can be put into practice for the generation of fractal interpolation functions for the earlier mentioned type of data (object).
Published: 2005

38. Theoretical and practical aspects of fractal interpolation function analysis

Author: Jančiukaitė, Giedrė, Janilionis, Vytautas, Saulis, Leonas, Valantinas, J., Barauskas, Arūnas, Rudzkis, Rimantas, Aksomaitis, Algirdas, Valakevičius, Eimutis, Navickas, Zenonas, and Kaunas University of Technology
Subjects: Fraktalinės interpoliacinės funkcijos, ComputingMethodologies_IMAGEPROCESSINGANDCOMPUTERVISION, MathematicsofComputing_NUMERICALANALYSIS, Fractal interpolation function, Mathematics, ComputingMethodologies_COMPUTERGRAPHICS
Abstract: This thesis introduces fractal interpolation functions, exposes advantages of fractal interpolation of real world objects and presents some newly developed procedures, associated with fractal interpolation process. The work briefly presents the context needed for introduction of fractal approach and relevant definitions. Also, the detailed description of fractal generating algorithms (deterministic, random iteration, “escape time”) as well as fractal classifications is presented. Since the research object is theoretical and practical aspects of fractal interpolation function analysis, special attention is paid to geometric fractals, obtained using systems of iterated functions (IFS). The notion of a fractal interpolation function is introduced in the work. The author shows that it is possible to generate fractal interpolation functions for various types of data. The generated functions are “close” (in the sense of Housdorf dimension) to the data under processing, i.e., it is possible to ensure that the fractal interpolation graph dimension were equal to the fractal dimension of experimental data (graph). The random iteration algorithm is used for the analysis of fractal interpolation functions, since it is relatively simple and fast enough. The author makes an attempt to analyze and solve the problem of choosing interpolation points (general case). A few approaches are proposed, namely the uniform distribution of interpolation points (for the interactive use) and collage. On... [to full text]
Published: 2005

39. Genotype Distribution and Characteristics of Chronic Hepatitis C Infection in Estonia, Latvia, Lithuania, and Ukraine: The RESPOND-C Study.

Author: Jančorienė L, Rozentāle B, Tolmane I, Jēruma A, Salupere R, Buivydienė A, Valantinas J, Kupčinskas L, Šumskienė J, Čiupkevičienė E, Ambrozaitis A, Golubovska O, Moroz L, Flisiak R, and Bondar B
Subjects: Humans, Lithuania epidemiology, Estonia epidemiology, Latvia epidemiology, Antiviral Agents, Ukraine epidemiology, Retrospective Studies, Hepacivirus genetics, Liver Cirrhosis epidemiology, Genotype, Hepatitis C, Chronic drug therapy, Hepatitis C, Chronic epidemiology, Hepatitis C
Abstract: Background and objectives: Since 2013, highly effective direct-acting antiviral (DAA) treatment for chronic hepatitis C (CHC) has become available, with cure rates exceeding 95%. For the choice of optimal CHC treatment, an assessment of the hepatitis C virus (HCV) genotype (GT) and liver fibrosis stage is necessary. Information about the distribution of these parameters among CHC patients in Estonia, Latvia, and Lithuania (the Baltic states) and especially in Ukraine is scarce. This study was performed to obtain epidemiologic data regarding CHC GT and fibrosis stage distribution for better planning of resources and prioritization of patients for DAA drug treatment according to disease severity in high-income (the Baltic states) and lower-middle-income (Ukraine) countries. Materials and methods: The retrospective RESPOND-C study included 1451 CHC patients. Demographic and disease information was collected from medical charts for each patient. Results: The most common suspected mode of viral transmission was blood transfusions (17.8%), followed by intravenous substance use (15.7%); however, in 50.9% of patients, the exact mode of transmission was not clarified. In Ukraine (18.4%) and Estonia (26%), transmission by intravenous substance use was higher than in Lithuania (5%) and Latvia (5.3%). Distribution of HCV GT among patients with CHC was as follows: GT1-66.4%; GT3-28.1; and GT2-4.1%. The prevalence of GT1 was the highest in Latvia (84%) and the lowest in Ukraine (63%, p < 0.001). Liver fibrosis stages were distributed as follows: F0-12.2%, F1-26.3%, F2-23.5%, F3-17.1%, and F4-20.9%. Cirrhosis (F4) was more prevalent in Lithuanian patients (30.1%) than in Estonians (8.1%, p < 0.001). Conclusions: This study contributes to the knowledge of epidemiologic characteristics of HCV infection in the Baltic states and Ukraine. The data regarding the patterns of HCV GT and fibrosis stage distribution will be helpful for the development of national strategies to control HCV infection in the era of DAA therapy.
Published: 2023
Full Text: View/download PDF

40. Metastatic multifocal melanoma of multiple organ systems: A case report.

Author: Maksimaityte V, Reivytyte R, Milaknyte G, Mickys U, Razanskiene G, Stundys D, Kazenaite E, Valantinas J, and Stundiene I
Abstract: Background: Malignant melanoma is becoming more common among middle-aged individuals all over the world. Melanoma metastasis can be found in various organs, although metastases to the spleen and stomach are rare. Herein we present a rare metastatic multifocal melanoma, clinically and histologically mimicking lymphoma, with metastases of multiple organs., Case Summary: A 46-year-old Caucasian male with a history of nodular cutaneous malignant melanoma was presented with nausea, general weakness, shortness of breath, abdominal enlargement, and night sweating. The abdominal ultrasound revealed enlarged liver and spleen with multiple lesions. Computed tomography demonstrated multiple lesions in the lungs, liver, spleen, subcutaneous tissue, bones and a pathological lymphadenopathy of the neck. Trephine biopsy and the biopsy from the enlarged lymph node were taken. Tumor cells showed diffuse or partial positivity for melanocytic markers, such as microphthalmia - associated transcription factor, S100, HMB45 and Melan-A. The tumor harbored BRAF V600E mutation, demonstrated by immunohistochemical labelling for BRAF V600E and detected by real-time polymerase chain reaction test. Having combined all the findings, a diagnosis was made of a metastatic multifocal melanoma of the stomach, duodenum, liver, spleen, lungs, lymph nodes and bones. The patient refused treatment and died a week later., Conclusion: This case report highlights the clinical relevance of rare metastatic multifocal melanoma of multiple organ systems., Competing Interests: Conflict-of-interest statement: The authors declare that they have no conflict of interest., (©The Author(s) 2022. Published by Baishideng Publishing Group Inc. All rights reserved.)
Published: 2022
Full Text: View/download PDF

41. Management of Flood syndrome: What can we do better?

Author: Strainiene S, Peciulyte M, Strainys T, Stundiene I, Savlan I, Liakina V, and Valantinas J
Subjects: Ascites, Floods, Humans, Liver Cirrhosis, SARS-CoV-2, COVID-19, Hernia, Umbilical
Abstract: Approximately 20% of cirrhotic patients with ascites develop umbilical herniation. These patients usually suffer from multisystemic complications of cirrhosis, have a significantly higher risk of infection, and require accurate surveillance- especially in the context of the coronavirus disease 2019 pandemic. The rupture of an umbilical hernia, is an uncommon, life-threatening complication of large-volume ascites and end-stage liver disease resulting in spontaneous paracentesis, also known as Flood syndrome. Flood syndrome remains a challenging condition for clinicians, as recommendations for its management are lacking, and the available evidence for the best treatment approach remains controversial. In this paper, four key questions are addressed regarding the management and prevention of Flood syndrome: (1) Which is the best treatment approach-conservative treatment or urgent surgery? (2) How can we establish the individual risk for herniation and possible hernia rupture in cirrhotic patients? (3) How can we prevent umbilical hernia ruptures? And (4) How can we manage these patients in the conditions created by the coronavirus disease 2019 pandemic?, Competing Interests: Conflict-of-interest statement: The authors declare that they have no conflicts of interest., (©The Author(s) 2021. Published by Baishideng Publishing Group Inc. All rights reserved.)
Published: 2021
Full Text: View/download PDF

42. Complicated course of biliary inflammatory myofibroblastic tumor mimicking hilar cholangiocarcinoma: A case report and literature review.

Author: Strainiene S, Sedleckaite K, Jarasunas J, Savlan I, Stanaitis J, Stundiene I, Strainys T, Liakina V, and Valantinas J
Abstract: Background: The inflammatory myofibroblastic tumor (IMT) is a rare, idiopathic, usually benign, mass-forming disease with myofibroblastic proliferation and a varying amount of inflammatory cells. Although it can affect various organs, the biliary tract is a rare localization of primary IMT, clinically, endoscopically and radiologically imitating cholangiocarcinoma. The treatment options are based only on clinical practice experience., Case Summary: A 70-year-old woman was referred to our center due to progressive fatigue, weight loss, abdominal pain, night sweats, and elevated liver enzymes. Magnetic resonance cholangiopancreatography and endoscopic retrograde cholangiopancreatography (ERCP) revealed proximal common hepatic duct and hilar biliary strictures extending bilaterally to lobular bile ducts. Although initial clinical, endoscopic and radiological signs were typical for hilar cholangiocarcinoma, histological examination showed no signs of malignancy. In total, 8 biopsies using different approaches were performed (several biopsies from dominant stricture during ERCP and direct cholangioscopy; ultrasound-guided liver biopsy; diagnostic laparoscopy with liver and lymph node biopsies). Histological examination revealed signs of IMT, and the final diagnosis of biliary IMT was stated. Although IMT is usually a benign disease, in our case, it was complicated. All pharmacological treatment measures were ineffective. The patient still needs permanent stenting, suffers from recurrent infections and mechanical jaundice. Despite that, the patient already survived 24 mo., Conclusion: IMT presenting with hilar biliary strictures is a unique diagnostic and clinical challenge as it is indistinguishable from cholangiocarcinoma, and there are no evidence-based treatment options. Our goal is to increase the understanding of this rare disease and its possible course., Competing Interests: Conflict-of-interest statement: The authors declare that they have no conflicts of interest., (©The Author(s) 2021. Published by Baishideng Publishing Group Inc. All rights reserved.)
Published: 2021
Full Text: View/download PDF

43. Comparison of Endoscopy First and Laparoscopic Cholecystectomy First Strategies for Patients With Gallstone Disease and Intermediate Risk of Choledocholithiasis: Protocol for a Clinical Randomized Controlled Trial.

Author: Aleknaite A, Simutis G, Stanaitis J, Jucaitis T, Drungilas M, Valantinas J, and Strupas K
Abstract: Background: The optimal approach for patients with gallbladder stones and intermediate risk of choledocholithiasis remains undetermined. The use of endoscopic retrograde cholangiopancreatography for diagnosis should be minimized as it carries considerable risk of postprocedural complications, and nowadays, less invasive and safer techniques are available., Objective: This study compares the two management strategies of endoscopic ultrasound before laparoscopic cholecystectomy and intraoperative cholangiography for patients with symptomatic cholecystolithiasis and intermediate risk of choledocholithiasis., Methods: This is a randomized, active-controlled, single-center clinical trial enrolling adult patients undergoing laparoscopic cholecystectomy for symptomatic gallbladder stones with intermediate risk of choledocholithiasis. The risk of choledocholithiasis is calculated using an original prognostic score (the Vilnius University Hospital Index). This index in a retrospective evaluation showed better prognostic performance than the score proposed by the American Society for Gastrointestinal Endoscopy in 2010. A total of 106 participants will be included and randomized into two groups. Evaluation of bile ducts using endoscopic ultrasound and endoscopic retrograde cholangiography on demand will be performed before laparoscopic cholecystectomy for one arm ("endoscopy first"). Intraoperative cholangiography during laparoscopic cholecystectomy and postoperative endoscopic retrograde cholangiopancreatography on demand will be performed in another arm ("cholecystectomy first"). Postoperative follow-up is 6 months. The primary endpoint is the length of hospital stay. The secondary endpoints are accuracy of the different management strategies, adverse events of the interventions, duct clearance and technical success of the interventions (intraoperative cholangiography, endoscopic ultrasound, and endoscopic retrograde cholangiography), and cost of treatment., Results: The trial protocol was approved by the Vilnius Regional Biomedical Research Ethics Committee in December 2017. Enrollment of patients was started in January 2018. As of June 2020, 66 patients have been enrolled., Conclusions: This trial is planned to determine the superior strategy for patients with intermediate risk of common bile duct stones and to define a simple and safe algorithm for managing choledocholithiasis., Trial Registration: ClinicalTrials.gov NCT03658863; https://clinicaltrials.gov/ct2/show/NCT03658863., International Registered Report Identifier (irrid): DERR1-10.2196/18837., (©Ausra Aleknaite, Gintaras Simutis, Juozas Stanaitis, Tomas Jucaitis, Mantas Drungilas, Jonas Valantinas, Kestutis Strupas. Originally published in JMIR Research Protocols (http://www.researchprotocols.org), 04.02.2021.)
Published: 2021
Full Text: View/download PDF

44. Paraneoplastic Phenomena of Disseminated Intravascular Coagulopathy in Hepatic Angiosarcoma - Rare, Challenging and Fatal. Case Report and Literature Review.

Author: Strainienė S, Jauniškis K, Savlan I, Pamedys J, Stundienė I, Liakina V, and Valantinas J
Abstract: Background: Hepatic angiosarcoma is an uncommon, malignant, primary liver tumor, comprising 2% of liver cancers and accounting for < 1% of all sarcomas. Patients usually present with nonspecific symptoms, such as fatigue, weight loss, right upper quadrant pain, anemia, which leads to late diagnosis of an advanced stage tumor. The median life expectancy after the diagnosis of hepatic angiosarcoma is about 6 months, with only 3% of patients surviving more than 2 years. Liver failure and hemoperitoneum are the leading causes of death in patients with liver angiosarcoma. In rarer cases, it might cause paraneoplastic syndromes such as disseminated intravascular coagulopathy. The treatment of angiosarcomas is complicated as there are no established and effective treatment guidelines due to the tumor's low frequency and aggressive nature., Case Summary: We present the case of a 68-year old woman who was admitted to the hospital due to fatigue and severe anemia (hemoglobin 65 g/l). Laboratory results also revealed high-grade thrombocytopenia (8 × 10 9 /l). The abdominal ultrasound and computed tomography scan showed multiple lesions throughout the liver, spleen and kidneys. After the histological examination of the liver biopsy, the patient was diagnosed with hepatic angiosarcoma. The treatment with first-line chemotherapy (doxorubicin) was initiated despite ongoing paraneoplastic syndrome - disseminative intravascular coagulopathy. However, the disease was terminal, and the patient died 2 months since diagnosed., Conclusions: Hepatic angiosarcoma is a rare and terminal tumor. Therefore, knowledge about its manifestations and effective treatment methods is lacking. Disseminative intravascular coagulopathy is a unique clinical characteristic of angiosarcoma seen in a subset of patients., (Copyright © 2021 Sandra Strainienė, Kipras Jaunškis, Ilona Savlan, Justinas Pamedys, Ieva Stundienė, Valentina Liakina, Jonas Valantinas.)
Published: 2021
Full Text: View/download PDF

45. Multi-organ IgG4-related disease continues to mislead clinicians: A case report and literature review.

Author: Strainiene S, Sarlauskas L, Savlan I, Liakina V, Stundiene I, and Valantinas J
Abstract: Background: Immunoglobulin G4-related disease (IgG4-RD) is a multisystemic mass forming immune-mediated disease that affects almost every organ and is a diagnostic challenge for every clinician. There is a lack of adequate epidemiological data worldwide, and evidence-based treatment recommendations are not yet established. We report the first case of IgG4-RD from Lithuania and the Baltic Sea region presented with thyroiditis, orbital myositis, orbitopathy, uveitis, scleritis, sialadenitis, autoimmune pancreatitis and prostatitis., Case Summary: A 54-year-old Caucasian male was admitted to our tertiary Centre complaining of severe weight loss, diarrhoea, abdominal pain, salivary gland swelling, sicca symptoms and diplopia. On examination, bilateral palpable masses in the projection of major salivary glands, severe protrusion of the left eyeball and cachexia were noted. The patient was previously diagnosed with autoimmune thyroiditis and endocrine ophthalmopathy. The magnetic resonance imaging (MRI) of the head revealed enlarged extraocular muscles indicating orbital myositis. The biopsy from the salivary gland mass indicated sialadenitis. Abdominal MRI showed signs of autoimmune pancreatitis, and a serological test revealed the elevated serum IgG4 concentration. The patient was then diagnosed with IgG4-RD and successfully treated with prednisolone. There was a significant clinical, serological and radiological improvement after one month of treatment and no signs of relapse within twenty months. However, it took almost 18 years and the efforts of eight different medical specialists to establish the correct diagnosis., Conclusion: A comprehensive approach to the patient is essential to improving the recognition of rare immune system conditions, such as IgG4-RD., Competing Interests: Conflict-of-interest statement: The authors declare that they have no conflicts of interest., (©The Author(s) 2020. Published by Baishideng Publishing Group Inc. All rights reserved.)
Published: 2020
Full Text: View/download PDF

46. Evaluation of Upper Endoscopic and Endoscopic Ultrasound Features in the Differential Diagnosis of Gastrointestinal Stromal Tumors and Leiomyomas in the Upper Gastrointestinal Tract.

Author: Vaicekauskas R, Urbonienė J, Stanaitis J, and Valantinas J
Abstract: Background: Differentiation between benign and malignant subepithelial lesions (SELs) in the upper gastrointestinal tract (UGT) leads to far-reaching clinical consequences. An accurate diagnosis can be challenging because of the insufficient diagnostic yield of upper endoscopy, endoscopic ultrasound (EUS), and different types of biopsy., Aim: Our aim was to reveal the efficacy of upper endoscopic and EUS features for the differential diagnosis of hypoechogenic SELs (gastrointestinal stromal tumors [GISTs] and leiomyomas) in the UGT., Materials and Methods: The research covers a case series study of 27 hypoechogenic SELs in the UGT between 2012 and 2015 at Vilnius University Hospital Santaros Klinikos. Upper endoscopic and EUS features of SELs were recorded. In order to standardize the diagnostic approach to GISTs and leiomyomas, we assigned scores for seven upper endoscopic and EUS features., Results: The mean total scores in the GIST group were significantly higher than those in the leiomyoma group: 3.25 ± 1.71 and 0.53 ± 0.83 ( p < 0.0001), respectively. Increment by one score increased the odds ratio for GIST 5.87 times (95% CI 1.63-21.11; p = 0.007). The total score demonstrated very good discriminatory features of GISTs against leiomyomas (area under the receiver operating characteristic curve 0.94 [0.86-1]). The cutoff value of 1.5 total score indicated 83.3% sensitivity and 93.3% specificity in diagnosing GISTs., Conclusions: Upper endoscopy and EUS are useful methods in making a definite diagnosis of SELs. Their diagnostic accuracy for the differential diagnosis of GISTs and leiomyomas is sufficient., Competing Interests: The authors declare no conflict of interest., (Copyright © 2019 by S. Karger AG, Basel.)
Published: 2020
Full Text: View/download PDF

47. Mucosa-associated lymphoid tissue lymphoma simulating Crohn's disease: A case report.

Author: Stundiene I, Maksimaityte V, Liakina V, and Valantinas J
Abstract: Background: Differential diagnosis between extranodal marginal zone lymphoma of mucosa-associated lymphoid tissue and inflammatory bowel disease is mainly based on histopathologic evaluation of intestinal biopsies, although there is no single definitive diagnostic investigation and that circumstance can lead to misdiagnosis in particular cases. Herein we present a rare, ulcerative form of marginal zone lymphoma which mimics the Crohn's disease (CD) of upper digestive tract., Case Summary: A 50-year-old man was presented with recurrent episodes of malaise and melena also weight loss. Enteroscopy of the small bowel demonstrated an ulcer in the jejunum. Microscopically, biopsies showed lymphoplasmacytic infiltrate. Diagnosis of CD was made. Primary treatment consisted of prednisone and azathioprine and was followed by azathioprine 100 mg per day with good clinical response in the following 2 years until relapse. At this time the results of endoscopic biopsies derived from proximal wall of stomach revealed Helicobacter pylori -negative marginal zone lymphoma of the gastric fundus. Immunophenotyping confirmed atypical CD20-positive cell population. Based on these biopsies, marginal zone lymphoma of mucosa-associated lymphoid tissue was diagnosed. Unfortunately, the contact with the patient was lost until one year later he was hospitalized with nausea, vomiting and severe pain because of gastrointestinal perforation. Four months later after laparotomy, the patient was treated with a course of chemotherapy. Complete remission was observed following 6 cycles of treatment., Conclusion: This case report highlights the clinical relevance of knowledge and awareness of marginal zone lymphoma simulating CD., Competing Interests: Conflict-of-interest statement: The authors declare that they have no conflict of interest., (©The Author(s) 2020. Published by Baishideng Publishing Group Inc. All rights reserved.)
Published: 2020
Full Text: View/download PDF

48. Liver cirrhosis and left ventricle diastolic dysfunction: Systematic review.

Author: Stundiene I, Sarnelyte J, Norkute A, Aidietiene S, Liakina V, Masalaite L, and Valantinas J
Subjects: Diastole physiology, Heart Ventricles physiopathology, Humans, Liver Cirrhosis diagnosis, Prevalence, Severity of Illness Index, Ventricular Dysfunction, Left diagnosis, Ventricular Dysfunction, Left etiology, Liver Cirrhosis complications, Ventricular Dysfunction, Left epidemiology
Abstract: Background: Liver cirrhosis is a chronic hepatic disease which is associated with cardiovascular abnormalities. Hyperdynamic circulation in liver cirrhosis causes functional and structural cardiac alterations. The prevalence of left ventricle diastolic dysfunction (LVDD) in cirrhotic patients ranges from 25.7% to as high as 81.4% as reported in different studies. In several studies the severity of diastolic dysfunction (DD) correlated with a degree of liver failure and the rate of dysfunction was higher in patients with decompensated cirrhosis compared with compensated. Future directions of comprehensive assessment of cardiac function in cirrhotic patients might provide a better prognosis for these patients., Aim: To clarify the correlation between the severity of liver cirrhosis and left ventricle diastolic dysfunction in the existing literature., Methods: Through January and February of 2019 at Vilnius University we conducted a systematic review of the global existing literature on the prevalence of left ventricle diastolic dysfunction in patients with liver cirrhosis. We searched for articles in PubMed, Medline and Web of science databases. Articles were selected by using adequate inclusion and exclusion criteria. Our interest was the outcome of likely correlation between the severity of cirrhosis [evaluated by Child-Pugh classes, Model For End-Stage Liver Disease (MELD) scores] and left ventricle diastolic dysfunction [classified according to American Society of Echocardiography (ASE) guidelines (2009, 2016)], as well as relative risk of dysfunction in cirrhotic patients. Subgroup analyses were performed to evaluate the ratio and grades of left ventricle diastolic dysfunction with respect to cirrhosis severity., Results: A total of 1149 articles and abstracts met the initial search criteria. Sixteen articles which met the predefined eligibility criteria were included in the final analysis. Overall, 1067 patients (out of them 723 men) with liver cirrhosis were evaluated for left ventricle diastolic dysfunction. In our systemic analysis we have found that 51.2% of cirrhotic patients had left ventricle diastolic dysfunction diagnosed and the grade 1 was the most prevalent (59.2%, P < 0.001) among them, the grade 3 had been rarely diagnosed - only 5.1%. The data about the prevalence of diastolic dysfunction in cirrhotic patients depending on Child-Pugh Classes was available from 5 studies (365 patients overall) and only in 1 research diastolic dysfunction was found being associated with severity of liver cirrhosis ( P < 0.005). We established that diastolic dysfunction was diagnosed in 44.6% of Child-Pugh A class patients, in 62% of Child B class and in 63.3% of Child C patients ( P = 0.028). The proportion of patients with higher diastolic dysfunction grades increases in more severe cirrhosis presentation ( P < 0.001). There was no difference between mean MELD scores in patients with and without diastolic dysfunction and in different diastolic dysfunction groups. In all studies diastolic dysfunction was more frequent in patients with ascites., Conclusion: This systemic analysis suggests that left ventricle diastolic dysfunction is an attribute of liver cirrhosis which has not received sufficient attention from clinicians so far. Future suggestions of a comprehensive assessment of cardiac function in cirrhotic patients might provide a better prognosis for these patients and give hint for better understanding of the left ventricle diastolic dysfunction pathogenesis in liver cirrhosis., Competing Interests: Peer-review started: April 22, 2019
Published: 2019
Full Text: View/download PDF

49. Changes in the Velocity of Blood in the Portal Vein in Mild Acute Pancreatitis-A Preliminary Clinical Study.

Author: Mickevičius A, Valantinas J, Stanaitis J, Jucaitis T, and Mašalaitė L
Subjects: Adult, Aged, Female, Follow-Up Studies, Hemodynamics, Humans, Male, Middle Aged, Pancreatitis blood, Prospective Studies, Blood Flow Velocity physiology, Pancreatitis physiopathology, Portal Vein physiopathology
Abstract: Background and objective : Portal vein thrombosis is associated with a decrease in the main blood velocity in this vessel. While most studies examine etiological factors of portal vein thrombosis after its occurrence, we aimed to evaluate portal vessels and assess whether mild acute pancreatitis affects blood flow in the portal vein and increases the risk of thrombosis. Materials and methods : This prospective single centered follow-up study enrolled 66 adult participants. Fifty of them were diagnosed with mild acute pancreatitis based on the Revised Atlanta classification, and 16 healthy participants formed the control group. All participants were examined three times. The first examination was carried out at the beginning of the disease and the next two at three-month intervals. Blood samples were taken and color Doppler ultrasound performed the first time, whereas ultrasound alone was performed during the second and third visits. Mean and maximal blood velocities and resistivity index in the main portal vein and its left and right branches were evaluated. Results : Mean velocity of the blood flow in the main portal vein and its right and left branches was not significantly different from healthy individuals during the acute pancreatitis phase: 23.1 ± 8.5 cm/s vs. 24.5 ± 8.2 cm/s ( p = 0.827); 16.4 ± 7.9 cm/s vs. 16.4 ± 8.1 cm/s ( p = 1.000); and 8 ± 3.4 cm/s vs. 7.4 ± 2.5 cm/s ( p = 0.826), respectively. The same was observed when comparing the maximal blood flow velocity: 67.9 ± 29 cm/s vs. 67.5 ± 21 cm/s ( p > 0.05); 45.4 ± 27 cm/s vs. 44 ± 23.8 cm/s ( p = 0.853); and 22.2 ± 9.8 cm/s vs. 20 ± 7.3 cm/s ( p = 0.926), respectively. Changes in venous blood velocities were not significant during the follow-up period in separate study groups. Conclusions : Portal blood flow velocities do not change during mild acute pancreatitis in the inflammatory and postinflammatory periods. This observation suggests that mild acute pancreatitis does not increase the risk of portal vein thrombosis.
Published: 2019
Full Text: View/download PDF

50. A case of ectopic pancreas in the ileum presenting as obscure gastrointestinal bleeding and abdominal pain.

Author: Mickuniene R, Stundiene I, Jucaitis T, Valanciene D, and Valantinas J
Subjects: Choristoma complications, Choristoma surgery, Humans, Ileal Diseases complications, Ileal Diseases surgery, Intestinal Polyps complications, Intestinal Polyps diagnostic imaging, Intestinal Polyps surgery, Magnetic Resonance Imaging methods, Male, Middle Aged, Abdominal Pain etiology, Choristoma diagnostic imaging, Gastrointestinal Hemorrhage etiology, Ileal Diseases diagnostic imaging, Pancreas
Abstract: Background: Ectopic pancreas is an infrequent submucosal tumor in the gastrointestinal tract defined as a pancreatic tissue lacking vascular or anatomic continuity with the main body of the pancreas. Ectopic pancreas in the ileum is a rare and often an incidental finding. We report a case of ectopic pancreas in the ileum causing obscure gastrointestinal bleeding and episodes of abdominal pain., Case Presentation: 59-year-old man with 3 months history of intermittent melena, accompanied by the episodes of abdominal pain in the left upper quadrant and generalized fatigue was admitted to our department. The investigations showed that the patient had a low hemoglobin level, i.e. 10.9 g/dL with hypochromic microcytic anemia pattern seen in complete blood count (MCV 70.2 fl, MCH 21.4 pg). Esophagogastroduodenoscopy and colonoscopy did not reveal any abnormalities. Magnetic resonance enterography revealed a large (2.5 × 2.3 cm) pedunculated polyp in the ileum. Examination by single-balloon enteroscopy revealed a polyp with long pedicle located approximately 1.5 m distal to terminal ileum. Polypectomy was performed. Histopathologic examination stated, that the specimen contained ectopic pancreatic tissue which was involving muscular layer of the ileum. Ectopic pancreatic tissue included acinar cells and cystically dilated secretory ducts without islets of Langerhans., Conclusion: Our case report reveals a very rare cause of obscure gastrointestinal bleeding accompanied by the episodes of abdominal pain - an ectopic pancreas located in the ileum.
Published: 2019
Full Text: View/download PDF

Catalog

Books, media, physical & digital resources

See catalog results

Searchworks

Select search scope, currently: Articles Catalog books, media & more in Jio Institute collections Articles journal articles & other e-resources

Search

Search Constraints

Refine your results

Search Limiters

Topic

Publication Year Range

Language

Publication Type

Journal

Region

Database

Publisher

101 results on '"Valantinas J."'

Search Results

Catalog

Select search scope, currently: Articles

Catalog

books, media & more in Jio Institute collections

Articles

journal articles & other e-resources